Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:pyridinecarboxamide
go back to main search page
Accession:CHEBI:25529 term browser browse the term
Definition:A member of the class of pyridines that is a substituted pyridine in which at least one of the substituents is a carboxamide or N-substituted caraboxamide group.
Synonyms:related_synonym: pyridinecarboxamides


show annotations for term's descendants           Sort by:
 
1-methylnicotinamide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cyp17a1 cytochrome P450, family 17, subfamily a, polypeptide 1 multiple interactions EXP N(1)-methylnicotinamide inhibits the reaction [Letrozole results in increased expression of CYP17A1 mRNA] CTD PMID:32298659 NCBI chr 1:266,422,127...266,429,947
Ensembl chr 1:266,422,132...266,428,239
JBrowse link
G Dek DEK proto-oncogene decreases chemical synthesis ISO DEK protein results in decreased chemical synthesis of N(1)-methylnicotinamide CTD PMID:28558019 NCBI chr17:17,965,872...17,987,836
Ensembl chr17:17,965,881...17,987,834
JBrowse link
G Lepr leptin receptor affects abundance ISO LEPR affects the abundance of N(1)-methylnicotinamide CTD PMID:20567778 NCBI chr 5:120,503,475...120,682,281
Ensembl chr 5:120,564,645...120,682,221
JBrowse link
G Lhb luteinizing hormone subunit beta multiple interactions EXP N(1)-methylnicotinamide inhibits the reaction [Letrozole results in increased secretion of LHB protein] CTD PMID:32298659 NCBI chr 1:101,409,992...101,413,725
Ensembl chr 1:101,410,019...101,413,724
JBrowse link
G Nampt nicotinamide phosphoribosyltransferase multiple interactions EXP N(1)-methylnicotinamide inhibits the reaction [Letrozole results in increased expression of NAMPT mRNA] CTD PMID:32298659 NCBI chr 6:52,122,085...52,156,473
Ensembl chr 6:52,122,085...52,156,472
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 increases expression EXP N(1)-methylnicotinamide results in increased expression of PTGS2 mRNA CTD PMID:18385449 NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
JBrowse link
G Retn resistin multiple interactions EXP N(1)-methylnicotinamide inhibits the reaction [Letrozole results in increased expression of RETN mRNA] CTD PMID:32298659 NCBI chr12:2,201,909...2,203,649
Ensembl chr12:2,201,891...2,204,249
JBrowse link
G Slc22a1 solute carrier family 22 member 1 increases import ISO SLC22A1 results in increased import of N(1)-methylnicotinamide CTD PMID:9260930 NCBI chr 1:48,273,639...48,300,645
Ensembl chr 1:48,273,611...48,300,655
JBrowse link
G Slc22a16 solute carrier family 22 member 16 multiple interactions ISO N(1)-methylnicotinamide inhibits the reaction [SLC22A16 protein results in increased uptake of Tetraethylammonium] CTD PMID:15963465 NCBI chr20:45,658,398...45,669,192 JBrowse link
G Slc22a2 solute carrier family 22 member 2 increases import ISO SLC22A2 results in increased import of N(1)-methylnicotinamide CTD PMID:9260930 NCBI chr 1:48,318,025...48,360,219
Ensembl chr 1:48,317,995...48,360,261
JBrowse link
G Slc22a3 solute carrier family 22 member 3 multiple interactions ISO N(1)-methylnicotinamide inhibits the reaction [SLC22A3 protein results in increased uptake of Tetraethylammonium] CTD PMID:10966924 NCBI chr 1:48,433,079...48,521,261
Ensembl chr 1:48,433,079...48,521,256
JBrowse link
CGP-42112A term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Agt angiotensinogen multiple interactions ISO CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX1 mRNA]; CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX1 protein]; CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX2 mRNA]; CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX2 protein]; CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX4 mRNA]; CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX4 protein]; CGP 42112A inhibits the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTRAP mRNA]]; CGP 42112A inhibits the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTRAP protein]]; CGP 42112A promotes the reaction [[AGT protein co-treated with Rotenone] results in increased expression of AGTR2 protein]; CGP 42112A promotes the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTR2 mRNA]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX1 mRNA]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX1 protein]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX2 mRNA]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX2 protein]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX4 mRNA]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTRAP mRNA]]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTRAP protein]]]; PD 123319 inhibits the reaction [CGP 42112A promotes the reaction [[AGT protein co-treated with Rotenone] results in increased expression of AGTR2 protein]]; PD 123319 inhibits the reaction [CGP 42112A promotes the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTR2 mRNA]]] CTD PMID:25446015 NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
JBrowse link
G Agtr2 angiotensin II receptor, type 2 multiple interactions ISO
EXP
CGP 42112A promotes the reaction [[AGT protein co-treated with Rotenone] results in increased expression of AGTR2 protein]; CGP 42112A promotes the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTR2 mRNA]]; PD 123319 inhibits the reaction [CGP 42112A promotes the reaction [[AGT protein co-treated with Rotenone] results in increased expression of AGTR2 protein]]; PD 123319 inhibits the reaction [CGP 42112A promotes the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTR2 mRNA]]]
[CGP 42112A binds to and results in increased activity of AGTR2 protein] which affects the susceptibility to Phenylephrine; [CGP 42112A binds to and results in increased activity of AGTR2 protein] which results in increased abundance of and results in increased secretion of Triglycerides; [CGP 42112A binds to and results in increased activity of AGTR2 protein] which results in increased abundance of Fatty Acids, Nonesterified; CGP 42112A binds to and results in increased activity of AGTR2 protein
CTD PMID:16003179, PMID:19151255, PMID:25446015 NCBI chr  X:119,389,480...119,393,845
Ensembl chr  X:119,390,013...119,393,842
JBrowse link
G Agtrap angiotensin II receptor-associated protein multiple interactions ISO CGP 42112A inhibits the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTRAP mRNA]]; CGP 42112A inhibits the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTRAP protein]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTRAP mRNA]]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTRAP protein]]] CTD PMID:25446015 NCBI chr 5:164,888,069...164,898,387
Ensembl chr 5:164,886,813...164,898,420
JBrowse link
G Cybb cytochrome b-245 beta chain multiple interactions ISO CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX2 mRNA]; CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX2 protein]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX2 mRNA]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX2 protein]] CTD PMID:25446015 NCBI chr  X:14,578,330...14,610,049
Ensembl chr  X:14,578,264...14,612,547
JBrowse link
G Nox1 NADPH oxidase 1 multiple interactions ISO CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX1 mRNA]; CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX1 protein]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX1 mRNA]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX1 protein]] CTD PMID:25446015 NCBI chr  X:104,909,328...104,932,508
Ensembl chr  X:104,909,326...104,932,508
JBrowse link
G Nox4 NADPH oxidase 4 multiple interactions ISO CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX4 mRNA]; CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX4 protein]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX4 mRNA]] CTD PMID:25446015 NCBI chr 1:150,796,359...150,976,186
Ensembl chr 1:150,797,084...150,976,194
JBrowse link
G Ube2v2 ubiquitin conjugating enzyme E2 V2 increases expression EXP CGP 42112A results in increased expression of UBE2V2 mRNA; CGP 42112A results in increased expression of UBE2V2 protein CTD PMID:17068200 NCBI chr11:89,557,273...89,591,175
Ensembl chr11:89,557,273...89,591,175
JBrowse link
isonicotinamide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Bglap bone gamma-carboxyglutamate protein increases expression EXP
ISO
isonicotinamide results in increased expression of BGLAP mRNA CTD PMID:16813520, PMID:21745208 NCBI chr 2:187,741,770...187,748,445
Ensembl chr 2:187,741,770...187,742,747
JBrowse link
G Fabp4 fatty acid binding protein 4 decreases expression
increases expression
ISO isonicotinamide results in decreased expression of FABP4 mRNA
isonicotinamide results in increased expression of FABP4 mRNA
CTD PMID:16813520 NCBI chr 2:93,792,666...93,797,267
Ensembl chr 2:93,792,601...93,797,305
JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma decreases expression ISO isonicotinamide results in decreased expression of PPARG mRNA CTD PMID:16813520 NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
JBrowse link
G Runx2 RUNX family transcription factor 2 increases expression ISO isonicotinamide results in increased expression of RUNX2 mRNA CTD PMID:21745208 NCBI chr 9:18,564,743...18,773,092
Ensembl chr 9:18,564,927...18,773,092
JBrowse link
G Sirt1 sirtuin 1 increases activity
increases expression
ISO isonicotinamide results in increased activity of SIRT1 protein
isonicotinamide results in increased expression of SIRT1 mRNA
CTD PMID:21745208 NCBI chr20:26,831,971...26,851,587
Ensembl chr20:26,833,357...26,852,199
JBrowse link
G Sp7 Sp7 transcription factor increases expression ISO isonicotinamide results in increased expression of SP7 mRNA CTD PMID:21745208 NCBI chr 7:143,957,316...143,967,488
Ensembl chr 7:143,958,858...143,967,484
JBrowse link
G Spp1 secreted phosphoprotein 1 increases expression ISO isonicotinamide results in increased expression of SPP1 mRNA CTD PMID:21745208 NCBI chr14:6,673,686...6,679,965
Ensembl chr14:6,673,686...6,679,901
JBrowse link
G Tnfrsf11b TNF receptor superfamily member 11B increases expression ISO isonicotinamide results in increased expression of TNFRSF11B mRNA CTD PMID:16813520 NCBI chr 7:93,798,580...93,826,586
Ensembl chr 7:93,798,545...93,826,665
JBrowse link
N-methyl-6-pyridone-3-carboxamide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Lepr leptin receptor affects abundance ISO LEPR affects the abundance of N'-methyl-2-pyridone-5-carboxamide CTD PMID:20567778 NCBI chr 5:120,503,475...120,682,281
Ensembl chr 5:120,564,645...120,682,221
JBrowse link
N-methylnicotinamide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Idh2 isocitrate dehydrogenase (NADP(+)) 2 increases abundance
multiple interactions
ISO IDH2 protein mutant form results in increased abundance of N-methylnicotinamide
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of N-methylnicotinamide]
CTD PMID:27469509 NCBI chr 1:141,874,354...141,893,674
Ensembl chr 1:141,866,283...141,893,705
JBrowse link
G Slco1a4 solute carrier organic anion transporter family, member 1a4 affects abundance ISO SLCO1A4 protein affects the abundance of N-methylnicotinamide CTD PMID:21561886 NCBI chr 4:175,969,549...176,026,227
Ensembl chr 4:175,969,549...176,026,163
JBrowse link
N-ribosylnicotinamide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ercc6 ERCC excision repair 6, chromatin remodeling factor multiple interactions ISO nicotinamide-beta-riboside inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of Adenosine Triphosphate]; nicotinamide-beta-riboside inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of NAD] CTD PMID:25440059 NCBI chr16:8,734,028...8,804,610
Ensembl chr16:8,734,035...8,804,610
JBrowse link
G Nqo2 N-ribosyldihydronicotinamide:quinone reductase 2 multiple interactions
increases oxidation
ISO [NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of 2,6-Dichloroindophenol; [NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q1; [NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q2; [NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Vitamin K 3; chrysoeriol inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q2]; chrysoeriol inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Vitamin K 3]; Melatonin inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q2]; Melatonin inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Vitamin K 3]; N-(2-(2-methoxy-6H-dipyrido(2,3-a-3,2-e)pyrrolizin-11-yl)ethyl)-2-furamide inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q2]; N-(2-(2-methoxy-6H-dipyrido(2,3-a-3,2-e)pyrrolizin-11-yl)ethyl)-2-furamide inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Vitamin K 3]; resveratrol inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q2]; resveratrol inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Vitamin K 3]
NQO2 protein results in increased oxidation of nicotinamide-beta-riboside; NQO2 protein results in increased oxidation of nicotinamide-beta-riboside metabolite
CTD PMID:20399199, PMID:29281794 NCBI chr17:32,131,847...32,158,559
Ensembl chr17:32,132,347...32,158,538
JBrowse link
nicorandil term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcc9 ATP binding cassette subfamily C member 9 increases activity ISO Nicorandil results in increased activity of ABCC9 protein CTD PMID:22622455 NCBI chr 4:176,806,098...176,928,540
Ensembl chr 4:176,805,431...176,922,424
JBrowse link
G Agt angiotensinogen multiple interactions ISO Nicorandil inhibits the reaction [AGT protein modified form results in increased expression of XDH protein] CTD PMID:22622455 NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions EXP Nicorandil inhibits the reaction [Doxorubicin results in increased expression of BAX protein] CTD PMID:31376360 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions EXP Nicorandil inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein] CTD PMID:31376360 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Cat catalase multiple interactions EXP Nicorandil inhibits the reaction [Doxorubicin results in decreased expression of CAT protein] CTD PMID:31376360 NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
JBrowse link
G Ctsd cathepsin D multiple interactions EXP [Nicorandil co-treated with Amlodipine] inhibits the reaction [Isoproterenol results in decreased activity of CTSD protein]; [Nicorandil co-treated with Amlodipine] inhibits the reaction [Isoproterenol results in increased activity of CTSD protein] CTD PMID:11829124, PMID:14499179 NCBI chr 1:215,541,570...215,553,446
Ensembl chr 1:215,541,542...215,553,451
JBrowse link
G Gal galanin and GMAP prepropeptide multiple interactions EXP [Nicorandil co-treated with Amlodipine] inhibits the reaction [Isoproterenol results in decreased activity of GAL protein]; [Nicorandil co-treated with Amlodipine] inhibits the reaction [Isoproterenol results in increased activity of GAL protein] CTD PMID:11829124, PMID:14499179 NCBI chr 1:218,653,059...218,657,922
Ensembl chr 1:218,652,917...218,657,925
JBrowse link
G Gusb glucuronidase, beta multiple interactions EXP [Nicorandil co-treated with Amlodipine] inhibits the reaction [Isoproterenol results in increased activity of GUSB protein] CTD PMID:11829124, PMID:14499179 NCBI chr12:30,202,066...30,215,583
Ensembl chr12:30,198,822...30,227,771
JBrowse link
G Havcr1 hepatitis A virus cellular receptor 1 multiple interactions EXP Nicorandil inhibits the reaction [Doxorubicin results in increased expression of HAVCR1 protein] CTD PMID:31376360 NCBI chr10:31,813,819...31,860,934
Ensembl chr10:31,813,814...31,848,379
JBrowse link
G Hmox1 heme oxygenase 1 decreases expression EXP Nicorandil results in decreased expression of HMOX1 protein CTD PMID:22622455 NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
JBrowse link
G Il1b interleukin 1 beta multiple interactions EXP Nicorandil inhibits the reaction [Doxorubicin results in increased expression of IL1B protein] CTD PMID:31376360 NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
JBrowse link
G Mpo myeloperoxidase multiple interactions EXP Nicorandil inhibits the reaction [Doxorubicin results in increased expression of MPO protein] CTD PMID:31376360 NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
JBrowse link
G Nfe2l2 nuclear factor, erythroid 2-like 2 multiple interactions EXP Nicorandil inhibits the reaction [Doxorubicin results in decreased expression of NFE2L2 protein] CTD PMID:31376360 NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 multiple interactions EXP Nicorandil inhibits the reaction [Doxorubicin results in increased expression of NFKB1 protein] CTD PMID:31376360 NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
JBrowse link
G Sod2 superoxide dismutase 2 increases expression EXP Nicorandil results in increased expression of SOD2 protein CTD PMID:22622455 NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
JBrowse link
G Tlr4 toll-like receptor 4 multiple interactions EXP Nicorandil inhibits the reaction [Doxorubicin results in increased expression of TLR4 protein] CTD PMID:31376360 NCBI chr 5:82,587,424...82,601,056
Ensembl chr 5:82,587,420...82,601,052
JBrowse link
G Tnf tumor necrosis factor multiple interactions EXP Nicorandil inhibits the reaction [Doxorubicin results in increased expression of TNF protein] CTD PMID:31376360 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
G Xdh xanthine dehydrogenase multiple interactions
decreases expression
ISO
EXP
Nicorandil inhibits the reaction [AGT protein modified form results in increased expression of XDH protein]
Nicorandil results in decreased expression of XDH protein
CTD PMID:22622455 NCBI chr 6:25,149,570...25,211,273
Ensembl chr 6:25,149,235...25,211,494
JBrowse link
nicotinamide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acaca acetyl-CoA carboxylase alpha multiple interactions
decreases phosphorylation
ISO
EXP
Niacinamide inhibits the reaction [6,8-diallyl 5,7-dihydroxy 2-(2-allyl 3-hydroxy 4-methoxyphenyl)1-H benzo(b)pyran-4-one results in increased phosphorylation of ACACA protein]
[Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased expression of ACACA mRNA]
Niacinamide results in decreased phosphorylation of ACACA protein
CTD PMID:18482975, PMID:19071085, PMID:21212096 NCBI chr10:71,519,392...71,719,910
Ensembl chr10:71,536,533...71,719,910
JBrowse link
G Adipoq adiponectin, C1Q and collagen domain containing increases secretion
multiple interactions
ISO
EXP
Niacinamide results in increased secretion of ADIPOQ protein
[Streptozocin co-treated with Niacinamide] results in decreased expression of ADIPOQ protein; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of ADIPOQ protein]
CTD PMID:17452443, PMID:21439372 NCBI chr11:81,330,845...81,344,488
Ensembl chr11:81,330,293...81,344,488
JBrowse link
G Ago2 argonaute RISC catalytic component 2 multiple interactions ISO Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of AGO2 mRNA]; Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of AGO2 protein] CTD PMID:24792773 NCBI chr 7:114,339,607...114,377,277
Ensembl chr 7:114,339,434...114,380,613
JBrowse link
G Agtr1a angiotensin II receptor, type 1a multiple interactions EXP [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [resveratrol results in decreased expression of AGTR1 mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased expression of AGTR1 mRNA CTD PMID:18420994 NCBI chr17:35,907,102...35,958,136
Ensembl chr17:35,907,108...35,958,077
JBrowse link
G Apaf1 apoptotic peptidase activating factor 1 multiple interactions ISO [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of APAF1 mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of APAF1 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of APAF1 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of APAF1 protein] CTD PMID:25478867 NCBI chr 7:31,699,309...31,784,192
Ensembl chr 7:31,699,885...31,784,192
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions
increases expression
EXP
ISO
Niacinamide inhibits the reaction [Methylnitrosourea results in increased expression of BAX protein]; Niacinamide inhibits the reaction [Thiotepa results in increased expression of BAX mRNA]; Niacinamide inhibits the reaction [Thiotepa results in increased expression of BAX protein]
[Berberine co-treated with Niacinamide] results in increased expression of BAX protein
[Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX protein]
Niacinamide results in increased expression of BAX mRNA; Niacinamide results in increased expression of BAX protein
CTD PMID:16168987, PMID:16998810, PMID:22164206, PMID:25478867, PMID:26712469 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Bbc3 Bcl-2 binding component 3 multiple interactions
increases expression
ISO [Berberine co-treated with Niacinamide] results in increased expression of BBC3 mRNA
Niacinamide results in increased expression of BBC3 mRNA
CTD PMID:26712469 NCBI chr 1:78,261,491...78,267,802 JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions ISO [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 protein]
[Berberine co-treated with Niacinamide] results in decreased expression of BCL2 protein; Niacinamide promotes the reaction [[Oxygen co-treated with Oxygen deficiency] results in decreased expression of BCL2 protein]
CTD PMID:25472572, PMID:25478867, PMID:26712469 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Bcl2l11 BCL2 like 11 multiple interactions
increases expression
ISO [Berberine co-treated with Niacinamide] results in increased expression of BCL2L11 mRNA; Niacinamide promotes the reaction [[Oxygen co-treated with Oxygen deficiency] results in increased expression of BCL2L11 protein]
Niacinamide results in increased expression of BCL2L11 mRNA
CTD PMID:25472572, PMID:26712469 NCBI chr 3:120,726,906...120,764,192
Ensembl chr 3:120,726,906...120,764,192
JBrowse link
G Bmi1 BMI1 proto-oncogene, polycomb ring finger multiple interactions ISO Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BMI1 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BMI1 protein] CTD PMID:24792773 NCBI chr17:85,360,439...85,370,283
Ensembl chr17:85,364,483...85,368,208
JBrowse link
G Casp3 caspase 3 multiple interactions
increases cleavage
EXP
ISO
Niacinamide inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein]; Niacinamide inhibits the reaction [Thiotepa results in increased activity of CASP3 protein]
Niacinamide results in increased cleavage of CASP3 protein
[Berberine co-treated with Niacinamide] results in increased cleavage of CASP3 protein; resveratrol inhibits the reaction [Niacinamide results in increased cleavage of CASP3 protein]
[Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CASP3 protein]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CASP3 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 protein]; Niacinamide promotes the reaction [Antimycin A results in increased cleavage of CASP3 protein]; Niacinamide promotes the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein]
CTD PMID:16505238, PMID:22164206, PMID:24040102, PMID:24962570, PMID:25478867, PMID:26712469 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Casp9 caspase 9 multiple interactions EXP
ISO
Niacinamide inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP9 protein]
[Berberine co-treated with Niacinamide] results in increased cleavage of CASP9 protein
[Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CASP9 protein]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CASP9 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 protein]
CTD PMID:16505238, PMID:25478867, PMID:26712469 NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
JBrowse link
G Cat catalase multiple interactions EXP [Niacinamide co-treated with Streptozocin] results in decreased activity of CAT protein; [Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein; coumarin inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of CAT protein]; Diosmin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of CAT protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; pioglitazone inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of CAT protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; Saponins inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; thymoquinone inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein] CTD PMID:20307516, PMID:21382363, PMID:21439372, PMID:21630391, PMID:22056647, PMID:23677724, PMID:29247773 NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 decreases expression ISO Niacinamide results in decreased expression of CCL2 protein CTD PMID:14627904 NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
JBrowse link
G Ccl20 C-C motif chemokine ligand 20 increases expression ISO Niacinamide results in increased expression of CCL20 mRNA CTD PMID:22385246 NCBI chr 9:88,918,359...88,921,017
Ensembl chr 9:88,918,433...88,921,001
JBrowse link
G Cd38 CD38 molecule multiple interactions ISO CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]] CTD PMID:20200208 NCBI chr14:71,714,768...71,754,990
Ensembl chr14:71,715,269...71,754,672
JBrowse link
G Cd40 CD40 molecule multiple interactions ISO Niacinamide promotes the reaction [TNF protein results in increased expression of CD40 mRNA] CTD PMID:22717288 NCBI chr 3:161,519,789...161,534,943
Ensembl chr 3:161,519,743...161,534,704
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A multiple interactions
increases expression
decreases expression
ISO
EXP
Niacinamide inhibits the reaction [tert-Butylhydroperoxide results in increased expression of CDKN1A protein]
Niacinamide results in increased expression of CDKN1A protein
Niacinamide inhibits the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1A protein]]
[Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN1A mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN1A protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN1A mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN1A protein]
Niacinamide results in decreased expression of CDKN1A protein
CTD PMID:12782109, PMID:22561310, PMID:25478867 NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B increases expression
multiple interactions
EXP Niacinamide results in increased expression of CDKN1B protein
Niacinamide inhibits the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1B protein]]
CTD PMID:22561310 NCBI chr 4:168,689,043...168,694,159
Ensembl chr 4:168,689,163...168,693,964
JBrowse link
G Cdkn2a cyclin-dependent kinase inhibitor 2A multiple interactions ISO Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN2A mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN2A protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased methylation of CDKN2A promoter] CTD PMID:24792773 NCBI chr 5:107,823,323...107,832,405
Ensembl chr 5:107,823,330...107,841,175
JBrowse link
G Chuk component of inhibitor of nuclear factor kappa B kinase complex increases activity
multiple interactions
ISO Niacinamide results in increased activity of CHUK protein
resveratrol inhibits the reaction [Niacinamide results in increased activity of CHUK protein]
CTD PMID:24962570 NCBI chr 1:263,848,829...263,884,354
Ensembl chr 1:263,848,884...263,885,169
JBrowse link
G Col1a1 collagen type I alpha 1 chain decreases expression
multiple interactions
ISO
EXP
Niacinamide results in decreased expression of COL1A1 mRNA
Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TGFB2 protein results in increased expression of COL1A1 mRNA]]
CTD PMID:16813520, PMID:25707573 NCBI chr10:82,745,801...82,762,790
Ensembl chr10:82,745,801...82,762,789
JBrowse link
G Col1a2 collagen type I alpha 2 chain multiple interactions ISO Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TGFB2 protein results in increased expression of COL1A2 mRNA]] CTD PMID:25707573 NCBI chr 4:31,534,225...31,569,152
Ensembl chr 4:31,534,225...31,569,151
JBrowse link
G Cyba cytochrome b-245 alpha chain multiple interactions
increases expression
EXP Clofibrate inhibits the reaction [Niacinamide results in increased expression of CYBA mRNA]; GW 6471 inhibits the reaction [Resveratrol inhibits the reaction [Niacinamide results in increased expression of CYBA mRNA]]; Resveratrol inhibits the reaction [Niacinamide results in increased expression of CYBA mRNA] CTD PMID:23422569 NCBI chr19:55,249,634...55,257,824
Ensembl chr19:55,249,616...55,257,876
JBrowse link
G Cyp17a1 cytochrome P450, family 17, subfamily a, polypeptide 1 multiple interactions EXP Niacinamide inhibits the reaction [Letrozole results in increased expression of CYP17A1 mRNA] CTD PMID:32298659 NCBI chr 1:266,422,127...266,429,947
Ensembl chr 1:266,422,132...266,428,239
JBrowse link
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 multiple interactions EXP [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA] CTD PMID:27919644 NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 multiple interactions EXP [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA] CTD PMID:27919644 NCBI chr12:11,641,500...11,677,818
Ensembl chr12:11,655,402...11,733,136
JBrowse link
G Defb4 defensin beta 4 multiple interactions ISO [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased expression of DEFB4A mRNA CTD PMID:24894820 NCBI chr16:75,634,598...75,637,789
Ensembl chr16:75,634,598...75,637,789
JBrowse link
G Dicer1 dicer 1 ribonuclease III multiple interactions ISO Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of DICER1 mRNA]; Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of DICER1 protein] CTD PMID:24792773 NCBI chr 6:128,388,084...128,453,234
Ensembl chr 6:128,388,053...128,434,183
JBrowse link
G Dlg1 discs large MAGUK scaffold protein 1 multiple interactions ISO [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased expression of DLG1 mRNA; Niacinamide inhibits the reaction [geranylgeranylacetone results in increased expression of DLG1 mRNA] CTD PMID:21232033 NCBI chr11:72,164,566...72,378,895
Ensembl chr11:72,163,749...72,378,895
JBrowse link
G Dnmt1 DNA methyltransferase 1 multiple interactions ISO Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of DNMT1 mRNA]; Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of DNMT1 protein] CTD PMID:24792773 NCBI chr 8:21,922,515...21,968,495
Ensembl chr 8:21,922,515...21,968,495
JBrowse link
G Eif4ebp1 eukaryotic translation initiation factor 4E binding protein 1 increases phosphorylation
multiple interactions
ISO Niacinamide results in increased phosphorylation of EIF4EBP1 protein
[Niacinamide results in decreased activity of SIRT1 protein] which results in increased phosphorylation of EIF4EBP1 protein; Niacinamide inhibits the reaction [Resveratrol results in decreased phosphorylation of EIF4EBP1 protein]
CTD PMID:19928762, PMID:20169165 NCBI chr16:68,954,860...68,968,248
Ensembl chr16:68,954,875...68,968,248
JBrowse link
G Ercc6 ERCC excision repair 6, chromatin remodeling factor increases abundance
multiple interactions
ISO ERCC6 gene mutant form results in increased abundance of Niacinamide
ERCC6 gene mutant form promotes the reaction [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride results in decreased abundance of Niacinamide]
CTD PMID:25440059 NCBI chr16:8,734,028...8,804,610
Ensembl chr16:8,734,035...8,804,610
JBrowse link
G F3 coagulation factor III, tissue factor decreases expression ISO Niacinamide results in decreased expression of F3 protein CTD PMID:14627904 NCBI chr 2:225,310,686...225,322,281
Ensembl chr 2:225,310,624...225,322,272
JBrowse link
G Faslg Fas ligand multiple interactions ISO CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]]; Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]] CTD PMID:20200208 NCBI chr13:79,696,811...79,717,581
Ensembl chr13:79,698,445...79,705,705
JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit multiple interactions EXP Niacinamide inhibits the reaction [Methylnitrosourea results in increased expression of FOS protein] CTD PMID:16168987 NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
JBrowse link
G Foxo1 forkhead box O1 multiple interactions ISO
EXP
Niacinamide inhibits the reaction [FOXO1 protein results in increased expression of G6PC mRNA]; Niacinamide inhibits the reaction [FOXO1 protein results in increased expression of IGFBP1 mRNA]
[Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of FOXO1 protein; Niacinamide results in increased expression of and results in increased acetylation of FOXO1 protein
Niacinamide inhibits the reaction [Dexamethasone results in decreased acetylation of FOXO1 protein]; Niacinamide inhibits the reaction [FOXO1 protein binds to SIRT1 protein]
CTD PMID:16917544, PMID:20181797, PMID:26712469 NCBI chr 2:141,451,234...141,527,016
Ensembl chr 2:141,451,234...141,527,016
JBrowse link
G Foxo3 forkhead box O3 multiple interactions ISO [Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of FOXO3 protein; Niacinamide inhibits the reaction [icariin inhibits the reaction [[Oxygen co-treated with Oxygen deficiency] results in increased acetylation of and results in increased expression of FOXO3 protein]]; Niacinamide inhibits the reaction [Resveratrol results in increased expression of FOXO3 protein]; Niacinamide promotes the reaction [[Oxygen co-treated with Oxygen deficiency] results in increased acetylation of FOXO3 protein]; Niacinamide results in increased expression of and results in increased acetylation of FOXO3 protein CTD PMID:23022493, PMID:25472572, PMID:26712469 NCBI chr20:46,428,078...46,519,156
Ensembl chr20:46,428,124...46,519,144
JBrowse link
G G6pc1 glucose-6-phosphatase catalytic subunit 1 multiple interactions ISO Niacinamide inhibits the reaction [FOXO1 protein results in increased expression of G6PC mRNA] CTD PMID:16917544 NCBI chr10:89,286,009...89,296,213
Ensembl chr10:89,285,855...89,296,213
JBrowse link
G G6pd glucose-6-phosphate dehydrogenase multiple interactions EXP [Streptozocin co-treated with Niacinamide] affects the activity of G6PD protein; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] affects the activity of G6PD protein] CTD PMID:19059388 NCBI chr  X:156,274,800...156,293,935
Ensembl chr  X:156,274,800...156,293,926
JBrowse link
G Gcg glucagon multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased expression of GCG mRNA; Sitagliptin Phosphate inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCG mRNA] CTD PMID:23466488 NCBI chr 3:48,442,635...48,451,650
Ensembl chr 3:48,442,635...48,451,650
JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC mRNA; [Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC protein; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC mRNA]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC mRNA]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC protein] CTD PMID:21439372 NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468
JBrowse link
G Glb1 galactosidase, beta 1 multiple interactions
increases expression
EXP Niacinamide inhibits the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of GLB1 protein]]
Niacinamide results in increased expression of GLB1 protein
CTD PMID:22561310 NCBI chr 8:122,439,328...122,511,939
Ensembl chr 8:122,439,328...122,511,939
JBrowse link
G Glo1 glyoxalase 1 multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased activity of GLO1 protein; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of GLO1 protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of GLO1 protein] CTD PMID:21439372 NCBI chr20:9,273,589...9,291,608
Ensembl chr20:9,273,594...9,291,610
JBrowse link
G Gsr glutathione-disulfide reductase multiple interactions EXP [Niacinamide co-treated with Streptozocin] results in decreased activity of GSR protein; [Streptozocin co-treated with Niacinamide] results in decreased activity of GSR protein; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of GSR protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of GSR protein]; Resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of GSR protein]; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of GSR protein] CTD PMID:20307516, PMID:21439372 NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
JBrowse link
G Gstm5 glutathione S-transferase, mu 5 multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased expression of GSTM3 mRNA; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GSTM3 mRNA]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GSTM3 mRNA] CTD PMID:21439372 NCBI chr 2:210,685,338...210,688,133
Ensembl chr 2:210,685,197...210,688,272
JBrowse link
G Gys2 glycogen synthase 2 multiple interactions EXP [Streptozocin co-treated with Niacinamide] affects the activity of GYS2 protein; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] affects the activity of GYS2 protein] CTD PMID:19059388 NCBI chr 4:176,638,632...176,679,805
Ensembl chr 4:176,638,629...176,679,815
JBrowse link
G Hba-a2 hemoglobin alpha, adult chain 2 multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in increased glycosylation of HBA1 protein; coumarin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased glycosylation of HBA1 protein] CTD PMID:19647726 NCBI chr10:15,589,364...15,590,207
Ensembl chr10:15,589,364...15,590,220
JBrowse link
G Hdac1 histone deacetylase 1 multiple interactions ISO Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of HDAC1 mRNA]; Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of HDAC1 protein] CTD PMID:24792773 NCBI chr 5:147,716,664...147,743,723
Ensembl chr 5:147,716,664...147,743,723
JBrowse link
G Hmgcr 3-hydroxy-3-methylglutaryl-CoA reductase multiple interactions EXP [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased expression of HMGCR mRNA]; [Streptozocin co-treated with Niacinamide] results in increased activity of HMGCR protein; [tetrahydrocurcumin co-treated with Chlorogenic Acid] results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in increased activity of HMGCR protein]; Chlorogenic Acid results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in increased activity of HMGCR protein]; tetrahydrocurcumin results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in increased activity of HMGCR protein] CTD PMID:20696151, PMID:21212096 NCBI chr 2:27,480,224...27,500,654
Ensembl chr 2:27,480,226...27,500,654
JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased expression of HMOX1 protein; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of HMOX1 protein]; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of HMOX1 protein] CTD PMID:21439372 NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
JBrowse link
G Icam1 intercellular adhesion molecule 1 multiple interactions ISO Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]] CTD PMID:24145604 NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
JBrowse link
G Ifng interferon gamma multiple interactions ISO [Niacinamide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA CTD PMID:29594315 NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
JBrowse link
G Igfbp1 insulin-like growth factor binding protein 1 multiple interactions ISO Niacinamide inhibits the reaction [FOXO1 protein results in increased expression of IGFBP1 mRNA] CTD PMID:16917544 NCBI chr14:87,448,716...87,453,783
Ensembl chr14:87,448,692...87,453,785
JBrowse link
G Il1b interleukin 1 beta multiple interactions
decreases expression
increases expression
EXP
ISO
[Niacinamide co-treated with Streptozocin] results in increased expression of IL1B protein; [Streptozocin co-treated with Niacinamide] results in increased expression of IL1B protein; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of IL1B protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of IL1B protein]; resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of IL1B protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of IL1B protein]
Niacinamide results in decreased expression of IL1B mRNA
Niacinamide results in increased expression of IL1B mRNA
CTD PMID:20307516, PMID:21439372, PMID:22385246, PMID:29594315 NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
JBrowse link
G Il2 interleukin 2 multiple interactions ISO [Niacinamide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 mRNA CTD PMID:29594315 NCBI chr 2:123,847,150...123,851,854
Ensembl chr 2:123,847,150...123,851,854
JBrowse link
G Il6 interleukin 6 decreases expression
multiple interactions
ISO
EXP
Niacinamide results in decreased expression of IL6 protein
[Niacinamide co-treated with Streptozocin] results in increased expression of IL6 protein; [Streptozocin co-treated with Niacinamide] results in increased expression of IL6 protein; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of IL6 protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of IL6 protein]; resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of IL6 protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of IL6 protein]
CTD PMID:12727023, PMID:20307516, PMID:21439372 NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
JBrowse link
G Ins2 insulin 2 multiple interactions ISO Niacinamide inhibits the reaction [Glucose inhibits the reaction [MAFA protein binds to INS promoter]]; Niacinamide inhibits the reaction [Glucose results in increased expression of INS mRNA]; Niacinamide inhibits the reaction [Glucose results in increased expression of INS protein] CTD PMID:16505238 NCBI chr 1:215,856,967...215,858,034
Ensembl chr 1:215,856,971...215,858,034
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions EXP Niacinamide inhibits the reaction [Methylnitrosourea results in increased expression of JUN protein]; Niacinamide inhibits the reaction [Methylnitrosourea results in increased phosphorylation of JUN protein] CTD PMID:16168987 NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
JBrowse link
G Keap1 Kelch-like ECH-associated protein 1 multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 mRNA; [Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 protein; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 mRNA]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 mRNA]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 protein] CTD PMID:21439372 NCBI chr 8:22,250,518...22,259,868
Ensembl chr 8:22,250,518...22,259,779
JBrowse link
G Lcat lecithin cholesterol acyltransferase multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased activity of LCAT protein; [tetrahydrocurcumin co-treated with Chlorogenic Acid] results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LCAT protein]; Chlorogenic Acid results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LCAT protein]; tetrahydrocurcumin results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LCAT protein] CTD PMID:20696151 NCBI chr19:37,913,333...37,916,799
Ensembl chr19:37,913,336...37,916,813
JBrowse link
G Lhb luteinizing hormone subunit beta multiple interactions EXP Niacinamide inhibits the reaction [Letrozole results in increased secretion of LHB protein] CTD PMID:32298659 NCBI chr 1:101,409,992...101,413,725
Ensembl chr 1:101,410,019...101,413,724
JBrowse link
G Lpl lipoprotein lipase multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased activity of LPL protein; [tetrahydrocurcumin co-treated with Chlorogenic Acid] results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LPL protein]; Chlorogenic Acid results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LPL protein]; tetrahydrocurcumin results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LPL protein] CTD PMID:20696151 NCBI chr16:22,537,687...22,561,487
Ensembl chr16:22,537,056...22,561,496
JBrowse link
G Mafa MAF bZIP transcription factor A multiple interactions ISO Niacinamide inhibits the reaction [Glucose inhibits the reaction [MAFA protein binds to INS promoter]] CTD PMID:16505238 NCBI chr 7:116,779,368...116,781,815
Ensembl chr 7:116,780,681...116,781,766
JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions ISO Niacinamide inhibits the reaction [[TNF protein co-treated with resveratrol] results in increased expression of MAP1LC3B protein alternative form] CTD PMID:24145604 NCBI chr19:53,635,449...53,643,970
Ensembl chr19:53,629,779...53,646,058
JBrowse link
G Mapk8 mitogen-activated protein kinase 8 multiple interactions EXP Niacinamide inhibits the reaction [Methylnitrosourea results in increased phosphorylation of MAPK8 protein] CTD PMID:16168987 NCBI chr16:9,620,854...9,709,342
Ensembl chr16:9,625,177...9,709,347
JBrowse link
G Mdm2 MDM2 proto-oncogene increases expression ISO Niacinamide results in increased expression of MDM2 mRNA CTD PMID:16998810 NCBI chr 7:60,719,060...60,743,618
Ensembl chr 7:60,719,066...60,743,328
JBrowse link
G Mir3545 microRNA 3545 multiple interactions ISO Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene affects the expression of MIR203 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased methylation of MIR203 promoter] CTD PMID:24792773 NCBI chr 6:136,704,947...136,705,061
Ensembl chr 6:136,704,947...136,705,061
JBrowse link
G Mmp9 matrix metallopeptidase 9 increases expression
multiple interactions
ISO Niacinamide results in increased expression of MMP9 protein
Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of MMP9 protein]]; resveratrol inhibits the reaction [Niacinamide results in increased expression of MMP9 protein]
CTD PMID:24145604, PMID:24962570 NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
JBrowse link
G Msra methionine sulfoxide reductase A multiple interactions ISO Niacinamide inhibits the reaction [resveratrol results in increased expression of MSRA protein] CTD PMID:23022493 NCBI chr15:47,488,333...47,800,662
Ensembl chr15:47,488,894...47,800,024
JBrowse link
G Mtor mechanistic target of rapamycin kinase increases phosphorylation
multiple interactions
ISO Niacinamide results in increased phosphorylation of MTOR protein
Niacinamide inhibits the reaction [resveratrol results in decreased phosphorylation of MTOR protein]
CTD PMID:19928762 NCBI chr 5:165,263,813...165,373,967
Ensembl chr 5:165,263,800...165,373,967
JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor multiple interactions ISO Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of MYC mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of MYC protein]; Niacinamide inhibits the reaction [Butylhydroxybutylnitrosamine results in increased expression of and results in increased localization of MYC protein] CTD PMID:22028816, PMID:24792773 NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
JBrowse link
G Nabp2 nucleic acid binding protein 2 decreases ubiquitination
increases acetylation
multiple interactions
ISO Niacinamide results in decreased ubiquitination of NABP2 protein
Niacinamide results in increased acetylation of NABP2 protein
Niacinamide promotes the reaction [trichostatin A results in decreased ubiquitination of NABP2 protein]; Niacinamide promotes the reaction [trichostatin A results in increased acetylation of NABP2 protein]; trichostatin A promotes the reaction [Niacinamide results in decreased ubiquitination of NABP2 protein]; trichostatin A promotes the reaction [Niacinamide results in increased acetylation of NABP2 protein]
CTD PMID:26170237 NCBI chr 7:2,820,006...2,825,627
Ensembl chr 7:2,820,007...2,825,608
JBrowse link
G Nampt nicotinamide phosphoribosyltransferase decreases expression
multiple interactions
ISO
EXP
Niacinamide results in decreased expression of NAMPT protein
Niacinamide inhibits the reaction [Letrozole results in increased expression of NAMPT mRNA]
[Berberine co-treated with Niacinamide] results in decreased expression of NAMPT protein
CTD PMID:26712469, PMID:32298659 NCBI chr 6:52,122,085...52,156,473
Ensembl chr 6:52,122,085...52,156,472
JBrowse link
G Ncor1 nuclear receptor co-repressor 1 decreases expression
multiple interactions
ISO Niacinamide results in decreased expression of NCOR1 protein
Niacinamide affects the reaction [PPARG protein binds to NCOR1 protein]
CTD PMID:22539994 NCBI chr10:48,629,121...48,772,890
Ensembl chr10:48,629,121...48,772,890
JBrowse link
G Ndufa1 NADH:ubiquinone oxidoreductase subunit A1 multiple interactions EXP Niacinamide inhibits the reaction [resveratrol results in increased expression of NDUFA1 mRNA] CTD PMID:23891692 NCBI chr  X:123,803,109...123,806,760
Ensembl chr  X:124,513,269...124,516,705
Ensembl chr  X:124,513,269...124,516,705
JBrowse link
G Ndufa13 NADH:ubiquinone oxidoreductase subunit A13 multiple interactions EXP Niacinamide inhibits the reaction [resveratrol results in increased expression of NDUFA13 mRNA]; Niacinamide inhibits the reaction [resveratrol results in increased expression of NDUFA13 protein] CTD PMID:23891692 NCBI chr16:21,275,311...21,282,246
Ensembl chr16:21,275,311...21,282,246
JBrowse link
G Ndufa2 NADH:ubiquinone oxidoreductase subunit A2 multiple interactions EXP Niacinamide inhibits the reaction [resveratrol results in increased expression of NDUFA2 mRNA] CTD PMID:23891692 NCBI chr18:29,585,671...29,587,760
Ensembl chr18:29,585,671...29,587,760
JBrowse link
G Nfe2l2 nuclear factor, erythroid 2-like 2 multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 mRNA; [Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 protein; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 mRNA]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 mRNA]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 protein] CTD PMID:21439372 NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions ISO Niacinamide inhibits the reaction [resveratrol results in decreased expression of NOS2 mRNA]; Niacinamide inhibits the reaction [resveratrol results in decreased expression of NOS2 protein] CTD PMID:23735732 NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
JBrowse link
G Nox4 NADPH oxidase 4 multiple interactions
increases expression
EXP GW 6471 inhibits the reaction [resveratrol inhibits the reaction [Niacinamide results in increased expression of NOX4 mRNA]]; resveratrol inhibits the reaction [Niacinamide results in increased expression of NOX4 mRNA] CTD PMID:23422569 NCBI chr 1:150,796,359...150,976,186
Ensembl chr 1:150,797,084...150,976,194
JBrowse link
G Nr4a1 nuclear receptor subfamily 4, group A, member 1 multiple interactions ISO [Glycerol co-treated with Succinic Acid co-treated with Glucose-6-Phosphate co-treated with Pantothenic Acid co-treated with Niacinamide] results in increased expression of NR4A1 mRNA CTD PMID:20505214 NCBI chr 7:142,899,358...142,920,216
Ensembl chr 7:142,905,758...142,920,216
JBrowse link
G Ogdh oxoglutarate dehydrogenase multiple interactions ISO Niacinamide inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased activity of OGDH protein] CTD PMID:18381761 NCBI chr14:86,414,924...86,481,903
Ensembl chr14:86,414,949...86,613,327
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
increases expression
increases cleavage
decreases activity
EXP
ISO
Niacinamide inhibits the reaction [Excitatory Amino Acid Agonists results in decreased expression of PARP1 protein]; Niacinamide inhibits the reaction [Excitatory Amino Acid Agonists results in increased activity of PARP1 protein]; Niacinamide inhibits the reaction [Methylnitrosourea results in increased activity of PARP1 protein]; Niacinamide inhibits the reaction [Thiotepa results in increased cleavage of PARP1 protein]
Niacinamide results in increased expression of PARP1 mRNA; Niacinamide results in increased expression of PARP1 protein
[Berberine co-treated with Niacinamide] results in increased cleavage of PARP1 protein
Niacinamide results in increased cleavage of PARP1 protein
Niacinamide results in decreased activity of PARP1 protein
CTD PMID:16168987, PMID:19288225, PMID:22164206, PMID:26712469, PMID:29143419 NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
JBrowse link
G Pdk4 pyruvate dehydrogenase kinase 4 multiple interactions EXP Niacinamide inhibits the reaction [Dexamethasone results in increased expression of PDK4 protein] CTD PMID:20181797 NCBI chr 4:30,546,772...30,556,774
Ensembl chr 4:30,546,664...30,556,814
JBrowse link
G Pdp1 pyruvate dehyrogenase phosphatase catalytic subunit 1 multiple interactions EXP Niacinamide inhibits the reaction [Dexamethasone results in increased phosphorylation of PDP1 protein] CTD PMID:20181797 NCBI chr 5:25,577,593...25,584,325
Ensembl chr 5:25,577,451...25,584,288
JBrowse link
G Pitx2 paired-like homeodomain 2 increases expression ISO Niacinamide results in increased expression of PITX2 mRNA; Niacinamide results in increased expression of PITX2 protein CTD PMID:29143419 NCBI chr 2:233,602,732...233,621,059
Ensembl chr 2:233,602,732...233,621,129
JBrowse link
G Pmp22 peripheral myelin protein 22 multiple interactions ISO Niacinamide inhibits the reaction [Butylhydroxybutylnitrosamine results in decreased expression of and results in decreased localization of PMP22 protein] CTD PMID:22028816 NCBI chr10:49,538,588...49,568,583
Ensembl chr10:49,538,588...49,568,583
JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma multiple interactions
increases expression
ISO Niacinamide affects the reaction [PPARG protein binds to NCOR1 protein]; resveratrol inhibits the reaction [Niacinamide results in increased expression of PPARG protein] CTD PMID:22539994 NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
JBrowse link
G Ppargc1a PPARG coactivator 1 alpha increases acetylation
multiple interactions
ISO
EXP
Niacinamide results in increased acetylation of PPARGC1A protein
[Niacinamide results in decreased activity of SIRT1 protein] which results in increased acetylation of PPARGC1A protein
[Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [SIRT1 protein results in increased expression of PPARGC1A mRNA]
CTD PMID:19071085, PMID:23422569, PMID:23891692 NCBI chr14:63,095,291...63,190,688
Ensembl chr14:63,095,720...63,187,009
JBrowse link
G Prkaa1 protein kinase AMP-activated catalytic subunit alpha 1 multiple interactions ISO Niacinamide inhibits the reaction [6,8-diallyl 5,7-dihydroxy 2-(2-allyl 3-hydroxy 4-methoxyphenyl)1-H benzo(b)pyran-4-one results in increased phosphorylation of PRKAA1 protein] CTD PMID:18482975 NCBI chr 2:54,857,688...54,893,404
Ensembl chr 2:54,857,688...54,893,404
JBrowse link
G Prkaa2 protein kinase AMP-activated catalytic subunit alpha 2 multiple interactions ISO Niacinamide inhibits the reaction [6,8-diallyl 5,7-dihydroxy 2-(2-allyl 3-hydroxy 4-methoxyphenyl)1-H benzo(b)pyran-4-one results in increased phosphorylation of PRKAA2 protein] CTD PMID:18482975 NCBI chr 5:124,568,845...124,642,569
Ensembl chr 5:124,574,079...124,642,569
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 increases expression
multiple interactions
ISO Niacinamide results in increased expression of PTGS2 protein
Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of PTGS2 protein]]; resveratrol inhibits the reaction [Niacinamide results in increased expression of PTGS2 protein]
CTD PMID:24145604, PMID:24962570 NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
JBrowse link
G Pygl glycogen phosphorylase L multiple interactions EXP [Streptozocin co-treated with Niacinamide] affects the activity of PYGL protein; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] affects the activity of PYGL protein] CTD PMID:19059388 NCBI chr 6:92,597,759...92,643,734
Ensembl chr 6:92,597,706...92,643,847
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions EXP
ISO
[Niacinamide co-treated with Streptozocin] results in increased expression of RELA protein; [Streptozocin co-treated with Niacinamide] results in increased activity of RELA protein; [Streptozocin co-treated with Niacinamide] results in increased expression of RELA protein; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of RELA protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of RELA protein]; Niacinamide inhibits the reaction [AICA ribonucleotide inhibits the reaction [Palmitic Acid results in increased phosphorylation of RELA protein]]; Niacinamide inhibits the reaction [Metformin inhibits the reaction [Palmitic Acid results in increased phosphorylation of RELA protein]]; Niacinamide inhibits the reaction [resveratrol inhibits the reaction [Palmitic Acid results in increased phosphorylation of RELA protein]]; Niacinamide inhibits the reaction [Salicylic Acid inhibits the reaction [Palmitic Acid results in increased phosphorylation of RELA protein]]; resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of RELA protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased activity of RELA protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of RELA protein]
Niacinamide results in increased acetylation of and results in increased phosphorylation of RELA protein; resveratrol inhibits the reaction [Niacinamide results in increased phosphorylation of and results in increased acetylation of RELA protein]
Niacinamide inhibits the reaction [resveratrol results in decreased expression of RELA protein modified form]; Niacinamide promotes the reaction [TNF protein results in increased acetylation of RELA protein]
CTD PMID:20307516, PMID:21439372, PMID:22717288, PMID:23406761, PMID:23735732, PMID:24962570, PMID:25108154 NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
JBrowse link
G Rps6 ribosomal protein S6 multiple interactions ISO [Niacinamide results in decreased activity of SIRT1 protein] which results in increased phosphorylation of RPS6 protein CTD PMID:20169165 NCBI chr 5:105,197,821...105,200,681
Ensembl chr 5:105,197,857...105,200,148
JBrowse link
G Runx2 RUNX family transcription factor 2 decreases expression
multiple interactions
increases expression
ISO
EXP
Niacinamide results in decreased expression of RUNX2 mRNA; Niacinamide results in decreased expression of RUNX2 protein
resveratrol inhibits the reaction [Niacinamide results in decreased expression of RUNX2 protein]
Niacinamide results in increased expression of RUNX2 mRNA
CTD PMID:16813520, PMID:22539994 NCBI chr 9:18,564,743...18,773,092
Ensembl chr 9:18,564,927...18,773,092
JBrowse link
G Shc1 SHC adaptor protein 1 multiple interactions
increases expression
ISO Niacinamide promotes the reaction [[Oxygen deficiency co-treated with Oxygen] results in increased expression of SHC1 protein]
Niacinamide results in increased expression of SHC1 mRNA; Niacinamide results in increased expression of SHC1 protein
CTD PMID:21778425, PMID:24557422 NCBI chr 2:188,745,503...188,757,066
Ensembl chr 2:188,745,503...188,757,066
JBrowse link
G Sirt1 sirtuin 1 multiple interactions
decreases expression
decreases activity
ISO
EXP
[Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [SIRT1 protein results in increased expression of PPARGC1A mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased expression of DLG1 mRNA; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to resveratrol; Niacinamide inhibits the reaction [[SIRT1 protein binds to UCP2 promoter] which results in decreased expression of UCP2 mRNA]
Niacinamide results in decreased expression of SIRT1 protein
[Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased abundance of Cholesterol]; [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased abundance of Glucose]; [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased expression of ACACA mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased expression of HMGCR mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Resveratrol results in decreased expression of AGTR1 mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to AICA ribonucleotide; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to Fructose; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to Metformin; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to Resveratrol; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to Salicylic Acid; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased acetylation of PPARGC1A protein; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased expression of AGTR1 mRNA; Niacinamide inhibits the reaction [Excitatory Amino Acid Agonists results in decreased expression of and results in decreased activity of SIRT1 protein]; Niacinamide inhibits the reaction [FOXO1 protein binds to SIRT1 protein]; Niacinamide inhibits the reaction [Resveratrol promotes the reaction [Pilocarpine results in increased expression of SIRT1 protein]]; Niacinamide inhibits the reaction [Resveratrol results in increased expression of SIRT1 mRNA]; Niacinamide inhibits the reaction [Resveratrol results in increased expression of SIRT1 protein]; Niacinamide inhibits the reaction [SIRT1 protein results in decreased abundance of NAD]
Niacinamide results in decreased expression of SIRT1 mRNA; Niacinamide results in decreased expression of SIRT1 protein
[Berberine co-treated with Niacinamide] results in decreased expression of SIRT1 protein; [Niacinamide results in decreased activity of SIRT1 protein] promotes the reaction [Hydrogen Peroxide results in increased acetylation of TP53 protein]; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased expression of DEFB4A mRNA; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased expression of CXCL8 mRNA; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased phosphorylation of EIF4EBP1 protein; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased phosphorylation of RPS6 protein; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased susceptibility to Hydrogen Peroxide; Niacinamide inhibits the reaction [1,5-dihydroxyisoquinoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased activity of SIRT1 protein]]; Niacinamide inhibits the reaction [icariin inhibits the reaction [[Oxygen co-treated with Oxygen deficiency] results in decreased expression of SIRT1 protein]]; Niacinamide inhibits the reaction [Resveratrol results in increased expression of SIRT1 protein]; Niacinamide inhibits the reaction [salvin inhibits the reaction [[Oxygen deficiency co-treated with Oxygen] results in decreased expression of SIRT1 protein]]; Niacinamide promotes the reaction [[Oxygen deficiency co-treated with Oxygen] results in decreased expression of SIRT1 protein]; Niacinamide results in decreased activity of [SIRT1 protein results in decreased acetylation of TP53 protein]
CTD PMID:16366736, PMID:17103016, PMID:18420994, PMID:18482975, PMID:18681908, PMID:19071085, PMID:19288225, PMID:19664641, PMID:19928762, PMID:20169165, PMID:20181797, PMID:21212096, PMID:21232033, PMID:21745208, PMID:21892612, PMID:22385246, PMID:22561310, PMID:22990594, PMID:23211629, PMID:23422569, PMID:23479127, PMID:23735732, PMID:23891692, PMID:24557422, PMID:24894820, PMID:25108154, PMID:25472572, PMID:25517228, PMID:26712469, PMID:28973641 NCBI chr20:26,831,971...26,851,587
Ensembl chr20:26,833,357...26,852,199
JBrowse link
G Sirt2 sirtuin 2 decreases activity
multiple interactions
ISO Niacinamide results in decreased activity of SIRT2 protein
[Berberine co-treated with Niacinamide] results in decreased expression of SIRT2 protein
CTD PMID:17341628, PMID:26712469 NCBI chr 1:86,948,866...86,971,954
Ensembl chr 1:86,948,918...86,971,952
JBrowse link
G Sirt3 sirtuin 3 multiple interactions ISO [Berberine co-treated with Niacinamide] results in decreased expression of SIRT3 protein CTD PMID:26712469 NCBI chr 1:213,613,502...213,636,061
Ensembl chr 1:213,613,513...213,635,546
JBrowse link
G Slc2a4 solute carrier family 2 member 4 multiple interactions EXP Niacinamide inhibits the reaction [Letrozole results in decreased expression of SLC2A4 mRNA] CTD PMID:32298659 NCBI chr10:56,552,921...56,558,562
Ensembl chr10:56,552,983...56,558,487
JBrowse link
G Slco1a4 solute carrier organic anion transporter family, member 1a4 affects abundance ISO SLCO1A4 protein affects the abundance of Niacinamide CTD PMID:21561886 NCBI chr 4:175,969,549...176,026,227
Ensembl chr 4:175,969,549...176,026,163
JBrowse link
G Snap23 synaptosome associated protein 23 multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased expression of SNAP23 mRNA; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of SNAP23 mRNA] CTD PMID:25999625 NCBI chr 3:112,333,972...112,362,960 JBrowse link
G Sod2 superoxide dismutase 2 multiple interactions EXP
ISO
Niacinamide inhibits the reaction [resveratrol results in increased expression of SOD2 mRNA]
Niacinamide promotes the reaction [[Oxygen co-treated with Oxygen deficiency] results in decreased expression of SOD2 protein]
CTD PMID:23891692, PMID:25472572 NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
JBrowse link
G Sox9 SRY-box transcription factor 9 decreases expression
multiple interactions
ISO Niacinamide results in decreased expression of SOX9 protein
4(2'-aminoethyl)amino-1,8-dimethylimidazo(1,2-a)quinoxaline inhibits the reaction [Niacinamide results in decreased expression of SOX9 protein]; resveratrol inhibits the reaction [Niacinamide results in decreased expression of SOX9 protein]
CTD PMID:24962570 NCBI chr10:101,288,528...101,294,030
Ensembl chr10:101,288,489...101,293,379
JBrowse link
G Sqstm1 sequestosome 1 multiple interactions ISO Niacinamide inhibits the reaction [Sirolimus results in decreased expression of SQSTM1 protein] CTD PMID:24238063 NCBI chr10:35,704,728...35,716,316
Ensembl chr10:35,704,730...35,716,294
JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 multiple interactions ISO Niacinamide inhibits the reaction [platycodin D inhibits the reaction [Glucose results in increased expression of SREBF1 protein]] CTD PMID:23319015 NCBI chr10:46,570,996...46,593,021
Ensembl chr10:46,570,996...46,593,009
JBrowse link
G Stx4 syntaxin 4 multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased expression of STX4 mRNA; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of STX4 mRNA] CTD PMID:25999625 NCBI chr 1:199,287,384...199,295,606
Ensembl chr 1:199,287,710...199,294,979
JBrowse link
G Tgfb2 transforming growth factor, beta 2 multiple interactions ISO Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TGFB2 protein results in increased expression of COL1A1 mRNA]]; Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TGFB2 protein results in increased expression of COL1A2 mRNA]] CTD PMID:25707573 NCBI chr13:105,039,639...105,142,010
Ensembl chr13:105,039,853...105,141,030
JBrowse link
G Tnf tumor necrosis factor multiple interactions
increases expression
EXP
ISO
[Niacinamide co-treated with Streptozocin] results in increased expression of TNF protein; [Streptozocin co-treated with Niacinamide] results in increased expression of TNF protein; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of TNF protein]; resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of TNF protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TNF protein]
Niacinamide inhibits the reaction [[TNF protein co-treated with resveratrol] results in increased expression of MAP1LC3B protein alternative form]; Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]; Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of MMP9 protein]]; Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of PTGS2 protein]]
Niacinamide promotes the reaction [TNF protein results in increased acetylation of RELA protein]; Niacinamide promotes the reaction [TNF protein results in increased expression of CD40 mRNA]
Niacinamide results in increased expression of TNF mRNA
CTD PMID:20307516, PMID:21439372, PMID:22385246, PMID:22717288, PMID:24145604 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
G Tnfrsf11b TNF receptor superfamily member 11B decreases expression ISO Niacinamide results in decreased expression of TNFRSF11B mRNA CTD PMID:16813520 NCBI chr 7:93,798,580...93,826,586
Ensembl chr 7:93,798,545...93,826,665
JBrowse link
G Tnfsf11 TNF superfamily member 11 decreases expression ISO Niacinamide results in decreased expression of TNFSF11 mRNA CTD PMID:16813520 NCBI chr15:60,482,527...60,512,704
Ensembl chr15:60,482,527...60,512,704
JBrowse link
G Tp53 tumor protein p53 multiple interactions
decreases expression
ISO [Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of TP53 protein; [Niacinamide results in decreased activity of SIRT1 protein] promotes the reaction [Hydrogen Peroxide results in increased acetylation of TP53 protein]; Niacinamide inhibits the reaction [tert-Butylhydroperoxide results in increased expression of TP53 protein]; Niacinamide results in decreased activity of [SIRT1 protein results in decreased acetylation of TP53 protein]; Niacinamide results in increased phosphorylation of and results in increased acetylation of TP53 protein
[Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of TRP53 mRNA alternative form]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of TRP53 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of TRP53 mRNA alternative form]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of TRP53 protein]
Niacinamide results in decreased expression of TP53 protein
CTD PMID:12782109, PMID:18482975, PMID:18681908, PMID:25478867, PMID:26712469 NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
JBrowse link
G Ucp2 uncoupling protein 2 multiple interactions ISO Niacinamide inhibits the reaction [[SIRT1 protein binds to UCP2 promoter] which results in decreased expression of UCP2 mRNA] CTD PMID:16366736 NCBI chr 1:165,506,375...165,512,744
Ensembl chr 1:165,506,361...165,512,744
JBrowse link
G Vamp2 vesicle-associated membrane protein 2 multiple interactions EXP [Streptozocin co-treated with Niacinamide] results in decreased expression of VAMP2 mRNA; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of VAMP2 mRNA] CTD PMID:25999625 NCBI chr10:55,675,171...55,679,405
Ensembl chr10:55,675,575...55,679,450
JBrowse link
regorafenib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Casp3 caspase 3 increases cleavage
increases activity
ISO regorafenib results in increased cleavage of CASP3 protein
regorafenib results in increased activity of CASP3 protein
CTD PMID:29341879, PMID:30801954 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Casp8 caspase 8 increases activity ISO regorafenib results in increased activity of CASP8 protein CTD PMID:30801954 NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
JBrowse link
G Ccnd1 cyclin D1 decreases expression ISO regorafenib results in decreased expression of CCND1 protein CTD PMID:30801954 NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
JBrowse link
G Fas Fas cell surface death receptor increases activity ISO regorafenib results in increased activity of FAS protein CTD PMID:30801954 NCBI chr 1:252,589,785...252,624,790
Ensembl chr 1:252,589,785...252,624,790
JBrowse link
G Faslg Fas ligand increases activity ISO regorafenib results in increased activity of FASLG protein CTD PMID:30801954 NCBI chr13:79,696,811...79,717,581
Ensembl chr13:79,698,445...79,705,705
JBrowse link
G Gpt glutamic--pyruvic transaminase increases secretion ISO regorafenib results in increased secretion of GPT protein CTD PMID:29655783 NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
JBrowse link
G Mapk1 mitogen activated protein kinase 1 decreases phosphorylation ISO regorafenib results in decreased phosphorylation of MAPK1 protein CTD PMID:30801954 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 decreases phosphorylation ISO regorafenib results in decreased phosphorylation of MAPK3 protein CTD PMID:30801954 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Mmp9 matrix metallopeptidase 9 decreases expression ISO regorafenib results in decreased expression of MMP9 protein CTD PMID:30801954 NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 increases cleavage ISO regorafenib results in increased cleavage of PARP1 protein CTD PMID:30801954 NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit decreases expression ISO regorafenib results in decreased expression of RELA protein CTD PMID:30801954 NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
JBrowse link
G Vegfa vascular endothelial growth factor A decreases expression ISO regorafenib results in decreased expression of VEGFA protein CTD PMID:30801954 NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
JBrowse link
G Xiap X-linked inhibitor of apoptosis decreases expression ISO regorafenib results in decreased expression of XIAP protein CTD PMID:30801954 NCBI chr  X:128,409,425...128,455,786
Ensembl chr  X:128,409,472...128,453,000
JBrowse link
sorafenib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb11 ATP binding cassette subfamily B member 11 decreases activity ISO sorafenib results in decreased activity of ABCB11 protein CTD PMID:20829430 NCBI chr 3:55,480,024...55,587,946
Ensembl chr 3:55,480,024...55,587,946
JBrowse link
G Abcc1 ATP binding cassette subfamily C member 1 affects response to substance ISO ABCC1 affects the susceptibility to sorafenib CTD PMID:24244338 NCBI chr10:549,537...672,235
Ensembl chr10:549,883...672,196
JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 affects response to substance ISO ABCC2 affects the susceptibility to sorafenib CTD PMID:24244338 NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252
JBrowse link
G Abcc3 ATP binding cassette subfamily C member 3 affects response to substance ISO ABCC3 affects the susceptibility to sorafenib CTD PMID:24244338 NCBI chr10:82,047,308...82,116,928
Ensembl chr10:82,047,863...82,117,109
JBrowse link
G Abl1 ABL proto-oncogene 1, non-receptor tyrosine kinase multiple interactions
decreases activity
decreases phosphorylation
ISO sorafenib inhibits the reaction [[ABL1 protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein]
sorafenib results in decreased activity of ABL1 protein mutant form
sorafenib results in decreased phosphorylation of ABL1 protein mutant form
CTD PMID:19366808 NCBI chr 3:10,041,820...10,145,076
Ensembl chr 3:10,041,826...10,144,388
JBrowse link
G Acta2 actin alpha 2, smooth muscle decreases expression EXP sorafenib results in decreased expression of ACTA2 mRNA CTD PMID:24321339 NCBI chr 1:252,537,614...252,550,394
Ensembl chr 1:252,537,615...252,550,394
JBrowse link
G Actg2 actin gamma 2, smooth muscle decreases expression EXP sorafenib results in decreased expression of ACTG2 mRNA CTD PMID:19338580 NCBI chr 4:115,215,160...115,239,746
Ensembl chr 4:115,215,060...115,239,723
JBrowse link
G Afp alpha-fetoprotein multiple interactions ISO Sorafenib inhibits the reaction [Diethylnitrosamine results in increased expression of AFP protein] CTD PMID:29859236 NCBI chr14:19,141,755...19,159,919
Ensembl chr14:19,141,755...19,159,923
JBrowse link
G Aifm1 apoptosis inducing factor, mitochondria associated 1 multiple interactions
affects localization
ISO [sorafenib co-treated with 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide] affects the localization of AIFM1 protein; [sorafenib co-treated with 6-bromoindirubin-3'-oxime] affects the localization of AIFM1 protein; [sorafenib co-treated with TNFSF10 protein] affects the localization of AIFM1 protein; GSK3B inhibits the reaction [sorafenib affects the localization of AIFM1 protein]
Sorafenib affects the localization of AIFM1 protein
CTD PMID:16109713, PMID:16959960, PMID:17909059, PMID:17991738, PMID:20054642, PMID:20117835 NCBI chr  X:135,304,063...135,343,062
Ensembl chr  X:135,304,066...135,343,087
JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions
increases phosphorylation
decreases phosphorylation
ISO 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [sorafenib results in decreased phosphorylation of AKT1 protein]; [Bortezomib co-treated with sorafenib] results in decreased phosphorylation of AKT1 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of CASP3 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of CASP9 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of PARP1 protein]; AKT1 protein results in decreased susceptibility to [Bortezomib co-treated with sorafenib]; Oxygen deficiency affects the reaction [2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [sorafenib results in decreased phosphorylation of AKT1 protein]]
Sorafenib results in increased phosphorylation of AKT1 protein
CTD PMID:16985072, PMID:21858812, PMID:23036488 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Atf4 activating transcription factor 4 multiple interactions
increases expression
ISO [[[sorafenib results in increased expression of ATF4 protein] which results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein] which results in decreased expression of BIRC5 protein; [[sorafenib results in increased expression of ATF4 protein] which results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein; sorafenib promotes the reaction [ATF4 protein results in increased expression of DDIT4 protein]
[sorafenib results in increased expression of ATF4 protein] which results in increased expression of DDIT3 mRNA; [sorafenib results in increased expression of ATF4 protein] which results in increased expression of DDIT3 protein; [sorafenib results in increased expression of ATF4 protein] which results in increased expression of DDIT4 protein; sorafenib results in increased expression of ATF4 mRNA; sorafenib results in increased expression of ATF4 protein
CTD PMID:21601561 NCBI chr 7:121,480,723...121,482,781
Ensembl chr 7:121,480,723...121,482,772
JBrowse link
G Atg5 autophagy related 5 multiple interactions
increases expression
ISO [Sorafenib co-treated with Vorinostat] promotes the reaction [FAS protein binds to CASP8 protein binds to ATG5 protein binds to HSPA5 protein]; [Sorafenib co-treated with Vorinostat] results in increased expression of ATG5 protein; ATG5 protein inhibits the reaction [[Sorafenib co-treated with Vorinostat] results in increased cleavage of CASP8 protein]; EIF2AK3 protein promotes the reaction [[Sorafenib co-treated with Vorinostat] promotes the reaction [CASP8 protein binds to ATG5 protein binds to HSPA5 protein binds to FAS protein]]; EIF2AK3 protein promotes the reaction [[Sorafenib co-treated with Vorinostat] results in increased expression of ATG5 protein]; FADD protein promotes the reaction [[Sorafenib co-treated with Vorinostat] promotes the reaction [CASP8 protein binds to ATG5 protein binds to HSPA5 protein binds to FAS protein]]; FADD protein promotes the reaction [[Sorafenib co-treated with Vorinostat] results in decreased expression of ATG5 protein]; FAS protein promotes the reaction [[Sorafenib co-treated with Vorinostat] results in decreased expression of ATG5 protein]
sorafenib results in increased expression of ATG5 protein
CTD PMID:18787411 NCBI chr20:49,301,783...49,393,147
Ensembl chr20:49,318,308...49,393,140
JBrowse link
G Bad BCL2-associated agonist of cell death increases expression
decreases expression
ISO sorafenib results in increased expression of BAD protein
sorafenib results in decreased expression of BAD mRNA
CTD PMID:18200035, PMID:21360571 NCBI chr 1:222,198,516...222,207,459
Ensembl chr 1:222,198,534...222,207,453
JBrowse link
G Bak1 BCL2-antagonist/killer 1 decreases expression
multiple interactions
increases expression
ISO sorafenib results in decreased expression of BAK1 protein
[sorafenib co-treated with TNFSF10 protein] affects the folding of and results in increased activity of BAK1 protein; MCL1 protein inhibits the reaction [[sorafenib co-treated with TNFSF10 protein] affects the folding of and results in increased activity of BAK1 protein]; sorafenib promotes the reaction [destruxin B results in increased expression of BAK1 protein]
sorafenib results in increased expression of BAK1 protein
CTD PMID:16109713, PMID:17909059, PMID:18200035, PMID:24434019 NCBI chr20:5,609,620...5,618,899
Ensembl chr20:5,609,625...5,618,260
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions
decreases expression
increases cleavage
increases expression
ISO [sorafenib co-treated with TNFSF10 protein] affects the folding of and results in increased activity of BAX protein; [sorafenib co-treated with TNFSF10 protein] affects the localization of BAX protein; BCL2L1 protein inhibits the reaction [sorafenib affects the folding of and results in increased activity of BAX protein]; MCL1 protein inhibits the reaction [[sorafenib co-treated with TNFSF10 protein] affects the folding of and results in increased activity of BAX protein]; sorafenib affects the folding of and results in increased activity of BAX protein
sorafenib results in decreased expression of BAX mRNA
sorafenib results in increased cleavage of BAX protein
sorafenib results in increased expression of BAX protein
CTD PMID:16109713, PMID:17909059, PMID:18200035, PMID:19366808, PMID:21360571 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions
decreases response to substance
increases cleavage
decreases expression
ISO [Paclitaxel co-treated with sorafenib] results in decreased expression of BCL2 protein; [sorafenib co-treated with Vitamin K 1] results in decreased expression of BCL2 protein; resveratrol promotes the reaction [sorafenib results in decreased expression of BCL2 protein]; sorafenib inhibits the reaction [Acids results in increased expression of BCL2 protein]; sorafenib inhibits the reaction [Taurocholic Acid results in increased expression of BCL2 protein]; sorafenib promotes the reaction [destruxin B results in decreased expression of BCL2 protein]
BCL2 protein results in decreased susceptibility to sorafenib
sorafenib results in increased cleavage of BCL2 protein
sorafenib results in decreased expression of BCL2 mRNA; sorafenib results in decreased expression of BCL2 protein
CTD PMID:16109713, PMID:17991738, PMID:18512153, PMID:19664330, PMID:19878585, PMID:20301194, PMID:20881478, PMID:24434019, PMID:26409325, PMID:26911335, PMID:28673964 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions
decreases expression
ISO [sorafenib co-treated with TNFSF10 protein] results in decreased expression of BCL2L1 protein; BCL2L1 protein inhibits the reaction [sorafenib affects the folding of and results in increased activity of BAX protein]; BCL2L1 protein inhibits the reaction [sorafenib results in increased cleavage of and results in increased activity of CASP3 protein]; resveratrol promotes the reaction [sorafenib results in decreased expression of BCL2L1 protein]; sorafenib promotes the reaction [destruxin B results in decreased expression of BCL2L1 protein]
Sorafenib results in decreased expression of BCL2L1 protein
CTD PMID:16109713, PMID:17909059, PMID:17991738, PMID:19366808, PMID:19633425, PMID:24434019, PMID:26911335 NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
JBrowse link
G Bcl2l11 BCL2 like 11 affects localization
increases expression
decreases expression
multiple interactions
ISO sorafenib affects the localization of BCL2L11 protein
sorafenib results in increased expression of BCL2L11 protein
sorafenib results in decreased expression of BCL2L11 protein
[sorafenib co-treated with 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] results in increased expression of BCL2L11 protein
CTD PMID:16109713, PMID:18200035, PMID:23036488 NCBI chr 3:120,726,906...120,764,192
Ensembl chr 3:120,726,906...120,764,192
JBrowse link
G Bcr BCR activator of RhoGEF and GTPase multiple interactions
decreases phosphorylation
decreases activity
ISO sorafenib inhibits the reaction [[BCR protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein]
sorafenib results in decreased phosphorylation of BCR protein mutant form
sorafenib results in decreased activity of BCR protein mutant form
CTD PMID:19366808 NCBI chr20:14,421,250...14,546,406
Ensembl chr20:14,421,141...14,545,772
JBrowse link
G Bid BH3 interacting domain death agonist multiple interactions ISO [sorafenib co-treated with TNFSF10 protein] promotes the reaction [CASP8 protein modified form results in increased cleavage of BID protein]; [sorafenib co-treated with TNFSF10 protein] results in increased cleavage of BID protein; [sorafenib co-treated with Vitamin K 1] results in increased cleavage of BID protein CTD PMID:17909059, PMID:20301194 NCBI chr 4:153,439,812...153,465,247
Ensembl chr 4:153,442,218...153,465,203
JBrowse link
G Birc3 baculoviral IAP repeat-containing 3 decreases expression ISO sorafenib results in decreased expression of BIRC3 protein CTD PMID:20473320 NCBI chr 8:6,048,590...6,076,828
Ensembl chr 8:6,048,969...6,076,598
JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 multiple interactions
decreases expression
ISO [[[Sorafenib results in increased expression of ATF4 protein] which results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein] which results in decreased expression of BIRC5 protein; [[Sorafenib results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein] which results in decreased expression of BIRC5 protein; [Resveratrol co-treated with Sorafenib] results in decreased expression of BIRC5 protein; Sorafenib inhibits the reaction [IGF1 protein results in increased expression of BIRC5 protein]
sorafenib analog results in decreased expression of BIRC5 protein; sorafenib results in decreased expression of BIRC5 mRNA; sorafenib results in decreased expression of BIRC5 protein
CTD PMID:18200035, PMID:20473320, PMID:21531053, PMID:21601561, PMID:26172295, PMID:26409325, PMID:26911335 NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413
JBrowse link
G Braf B-Raf proto-oncogene, serine/threonine kinase multiple interactions
decreases activity
ISO
EXP
Sorafenib inhibits the reaction [BRAF protein mutant form results in increased phosphorylation of MAPK1 protein]; Sorafenib inhibits the reaction [BRAF protein mutant form results in increased phosphorylation of MAPK3 protein]
sorafenib results in decreased activity of BRAF protein
sorafenib results in decreased activity of BRAF protein; sorafenib results in decreased activity of BRAF protein mutant form
CTD PMID:17341847, PMID:17664273, PMID:20823850 NCBI chr 4:67,389,331...67,520,549
Ensembl chr 4:67,396,192...67,520,356
JBrowse link
G Casp3 caspase 3 multiple interactions
increases expression
decreases expression
increases cleavage
increases activity
affects cleavage
ISO [Bortezomib co-treated with sorafenib] results in increased cleavage of CASP3 protein; [sorafenib co-treated with 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] results in increased cleavage of CASP3 protein; [sorafenib co-treated with 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide] results in increased cleavage of CASP3 protein; [sorafenib co-treated with PRKN protein] results in decreased expression of CASP3 protein; [sorafenib co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP3 protein; [sorafenib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein; [sorafenib co-treated with Vitamin K 1] results in increased cleavage of CASP3 protein; [sorafenib co-treated with vorinostat] results in increased cleavage of CASP3 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of CASP3 protein]; arsenic trioxide promotes the reaction [sorafenib results in decreased expression of CASP3 protein]; arsenic trioxide promotes the reaction [sorafenib results in increased activity of CASP3 protein]; BCL2L1 protein inhibits the reaction [sorafenib results in increased cleavage of and results in increased activity of CASP3 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of CASP3 protein]; Boc-D-FMK inhibits the reaction [sorafenib results in increased cleavage of and results in increased activity of CASP3 protein]; resveratrol promotes the reaction [sorafenib results in increased cleavage of CASP3 protein]; sorafenib inhibits the reaction [TGFB1 protein results in increased activity of CASP3 mRNA]; sorafenib promotes the reaction [arsenic trioxide results in decreased expression of CASP3 protein]; sorafenib promotes the reaction [arsenic trioxide results in increased activity of CASP3 protein]; sorafenib results in increased cleavage of and results in increased activity of CASP3 protein
Sorafenib results in increased expression of CASP3 protein modified form
sorafenib results in decreased expression of CASP3 mRNA
sorafenib affects the cleavage of CASP3 protein
CTD PMID:16007148, PMID:16109713, PMID:16985072, PMID:17909059, PMID:18200035, PMID:18787411, PMID:19366808, PMID:19770576, PMID:20071162, PMID:20117835, PMID:20301194, PMID:20473320, PMID:21293487, PMID:21360571, PMID:23036488, PMID:25416439, PMID:26409325, PMID:26911335, PMID:28673964, PMID:32634519 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Casp7 caspase 7 increases activity
multiple interactions
ISO sorafenib results in increased activity of CASP7 protein
[sorafenib co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP7 protein; sorafenib results in increased cleavage of and results in increased activity of CASP7 protein
CTD PMID:16109713, PMID:17909059, PMID:19770576, PMID:20054642 NCBI chr 1:277,190,557...277,242,779
Ensembl chr 1:277,190,964...277,242,774
JBrowse link
G Casp8 caspase 8 multiple interactions
increases cleavage
affects localization
ISO [sorafenib co-treated with TNFSF10 protein] promotes the reaction [CASP8 protein modified form results in increased cleavage of BID protein]; [sorafenib co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP8 protein; [sorafenib co-treated with TNFSF10 protein] results in increased cleavage of CASP8 protein; [sorafenib co-treated with Vitamin K 1] results in increased cleavage of CASP8 protein; [sorafenib co-treated with vorinostat] promotes the reaction [CASP8 protein binds to FAS protein binds to FADD protein]; [sorafenib co-treated with vorinostat] promotes the reaction [FAS protein binds to CASP8 protein binds to ATG5 protein binds to HSPA5 protein]; [sorafenib co-treated with vorinostat] results in increased cleavage of CASP8 protein; ATG5 protein inhibits the reaction [[sorafenib co-treated with vorinostat] results in increased cleavage of CASP8 protein]; Boc-D-FMK inhibits the reaction [sorafenib results in increased cleavage of and results in increased activity of CASP8 protein]; EIF2AK3 protein promotes the reaction [[sorafenib co-treated with vorinostat] promotes the reaction [CASP8 protein binds to ATG5 protein binds to HSPA5 protein binds to FAS protein]]; EIF2AK3 protein promotes the reaction [[sorafenib co-treated with vorinostat] promotes the reaction [FAS protein binds to FADD protein binds to CASP8 protein]]; EIF2AK3 protein promotes the reaction [[sorafenib co-treated with vorinostat] results in increased cleavage of CASP8 protein]; FADD protein promotes the reaction [[sorafenib co-treated with vorinostat] promotes the reaction [CASP8 protein binds to ATG5 protein binds to HSPA5 protein binds to FAS protein]]; sorafenib results in increased cleavage of and results in increased activity of CASP8 protein
sorafenib results in increased cleavage of CASP8 protein
sorafenib affects the localization of CASP8 protein modified form
CTD PMID:16007148, PMID:16109713, PMID:17909059, PMID:18200035, PMID:18787411, PMID:20071162, PMID:20301194 NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
JBrowse link
G Casp9 caspase 9 multiple interactions
increases cleavage
increases activity
ISO [Bortezomib co-treated with sorafenib] results in increased cleavage of CASP9 protein; [sorafenib co-treated with 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide] results in increased cleavage of CASP9 protein; [sorafenib co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP9 protein; [sorafenib co-treated with TNFSF10 protein] results in increased cleavage of CASP9 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of CASP9 protein]; arsenic trioxide promotes the reaction [sorafenib results in increased activity of CASP9 protein]; MCL1 protein inhibits the reaction [sorafenib results in increased cleavage of and results in increased activity of CASP9 protein]; sorafenib promotes the reaction [arsenic trioxide results in increased activity of CASP9 protein]; sorafenib results in increased cleavage of and results in increased activity of CASP9 protein
sorafenib results in increased cleavage of CASP9 protein
CTD PMID:16109713, PMID:16985072, PMID:17909059, PMID:18200035, PMID:20054642, PMID:20071162, PMID:20117835, PMID:21293487, PMID:25416439 NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
JBrowse link
G Ccn2 cellular communication network factor 2 decreases expression ISO Sorafenib results in decreased expression of CCN2 mRNA CTD PMID:21360571 NCBI chr 1:21,851,657...21,854,773
Ensembl chr 1:21,851,660...21,854,773
JBrowse link
G Ccna2 cyclin A2 decreases expression ISO sorafenib results in decreased expression of CCNA2 protein CTD PMID:19139124 NCBI chr 2:123,274,727...123,282,266
Ensembl chr 2:123,275,881...123,282,214
JBrowse link
G Ccnb1 cyclin B1 decreases expression ISO sorafenib results in decreased expression of CCNB1 protein CTD PMID:19139124 NCBI chr 2:30,782,133...30,791,106
Ensembl chr 2:30,783,915...30,791,221
JBrowse link
G Ccnd1 cyclin D1 decreases expression
multiple interactions
ISO
EXP
sorafenib analog results in decreased expression of CCND1 protein; sorafenib results in decreased expression of CCND1 mRNA; sorafenib results in decreased expression of CCND1 protein
Sorafenib inhibits the reaction [Diethylnitrosamine results in increased expression of CCND1 mRNA]
sorafenib inhibits the reaction [[Theophylline results in increased abundance of Cyclic AMP] which results in increased expression of CCND1 protein]; sorafenib inhibits the reaction [TSC2 protein mutant form results in increased expression of CCND1 protein]
[sorafenib co-treated with letrozole] results in decreased expression of CCND1 protein; [sorafenib co-treated with rottlerin] results in decreased expression of CCND1 protein; arsenic trioxide promotes the reaction [sorafenib results in decreased expression of CCND1 protein]; sorafenib inhibits the reaction [Acids results in increased expression of CCND1 mRNA]; sorafenib inhibits the reaction [Acids results in increased expression of CCND1 protein]; sorafenib inhibits the reaction [Taurocholic Acid results in increased expression of CCND1 mRNA]; sorafenib inhibits the reaction [Taurocholic Acid results in increased expression of CCND1 protein]; sorafenib promotes the reaction [arsenic trioxide results in decreased expression of CCND1 protein]
CTD PMID:16959960, PMID:17178882, PMID:17909054, PMID:18512153, PMID:18840136, PMID:19001435, PMID:19633425, PMID:19878585, PMID:20054642, PMID:21531053, PMID:21693435, PMID:21813464, PMID:25416439, PMID:29859236 NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
JBrowse link
G Ccnd2 cyclin D2 decreases expression ISO sorafenib results in decreased expression of CCND2 protein CTD PMID:19001435 NCBI chr 4:159,674,885...159,697,207
Ensembl chr 4:159,674,885...159,697,207
JBrowse link
G Ccnd3 cyclin D3 multiple interactions
decreases expression
ISO [sorafenib co-treated with rottlerin] results in decreased expression of CCND3 protein
sorafenib results in decreased expression of CCND3 protein
CTD PMID:16959960, PMID:19001435 NCBI chr 9:15,404,816...15,410,905
Ensembl chr 9:15,404,822...15,410,943
JBrowse link
G Ccne1 cyclin E1 multiple interactions ISO sorafenib inhibits the reaction [Acids results in increased expression of CCNE1 protein]; sorafenib inhibits the reaction [Taurocholic Acid results in increased expression of CCNE1 protein] CTD PMID:18512153 NCBI chr 1:94,485,830...94,495,112
Ensembl chr 1:94,485,832...94,494,980
JBrowse link
G Cdh1 cadherin 1 multiple interactions
increases expression
ISO sorafenib inhibits the reaction [TGFB1 protein results in decreased expression of CDH1 protein]; sorafenib promotes the reaction [destruxin B results in increased expression of CDH1 protein]
sorafenib results in increased expression of CDH1 protein
CTD PMID:21360571, PMID:24434019 NCBI chr19:38,768,467...38,838,395
Ensembl chr19:38,768,467...38,838,395
JBrowse link
G Cdh2 cadherin 2 multiple interactions ISO sorafenib promotes the reaction [destruxin B results in decreased expression of CDH2 protein] CTD PMID:24434019 NCBI chr18:8,146,971...8,366,037
Ensembl chr18:8,146,971...8,360,684
JBrowse link
G Cdk1 cyclin-dependent kinase 1 decreases expression ISO sorafenib results in decreased expression of CDK1 protein CTD PMID:19139124 NCBI chr20:20,576,341...20,591,510
Ensembl chr20:20,576,377...20,591,549
JBrowse link
G Cdk2 cyclin dependent kinase 2 decreases expression ISO sorafenib results in decreased expression of CDK2 mRNA CTD PMID:26409325 NCBI chr 7:3,124,953...3,132,533
Ensembl chr 7:3,124,954...3,132,457
JBrowse link
G Cdk4 cyclin-dependent kinase 4 multiple interactions
decreases expression
ISO [sorafenib co-treated with rottlerin] results in decreased expression of CDK4 protein
sorafenib results in decreased expression of CDK4 protein
CTD PMID:16959960 NCBI chr 7:70,345,971...70,352,689
Ensembl chr 7:70,349,863...70,352,418
JBrowse link
G Cdk6 cyclin-dependent kinase 6 multiple interactions
decreases expression
ISO [sorafenib co-treated with rottlerin] results in decreased expression of CDK6 protein
sorafenib results in decreased expression of CDK6 protein
CTD PMID:16959960 NCBI chr 4:27,781,728...27,969,653
Ensembl chr 4:27,785,647...27,966,398
JBrowse link
G Cdk9 cyclin-dependent kinase 9 decreases expression ISO sorafenib results in decreased expression of CDK9 mRNA CTD PMID:26409325 NCBI chr 3:11,742,269...11,747,117
Ensembl chr 3:11,742,266...11,747,113
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A decreases expression ISO sorafenib results in decreased expression of CDKN1A protein CTD PMID:19139124 NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B multiple interactions
decreases expression
increases expression
ISO
EXP
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [sorafenib results in increased expression of CDKN1B protein]; sorafenib promotes the reaction [2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine results in increased expression of CDKN1B protein]
sorafenib results in decreased expression of CDKN1B protein
sorafenib inhibits the reaction [[Theophylline results in increased abundance of Cyclic AMP] which results in increased expression of CDKN1B protein]
CTD PMID:19139124, PMID:19878585, PMID:21693435, PMID:23036488 NCBI chr 4:168,689,043...168,694,159
Ensembl chr 4:168,689,163...168,693,964
JBrowse link
G Cdkn2b cyclin-dependent kinase inhibitor 2B increases expression ISO sorafenib results in increased expression of CDKN2B protein CTD PMID:19139124 NCBI chr 5:107,834,353...107,857,428
Ensembl chr 5:107,845,951...107,858,104
JBrowse link
G Cebpd CCAAT/enhancer binding protein delta multiple interactions
increases expression
ISO sorafenib promotes the reaction [CEBPD protein binds to GADD45G promoter]
sorafenib results in increased expression of CEBPD protein
CTD PMID:26172295 NCBI chr11:89,008,008...89,009,146
Ensembl chr11:89,008,008...89,009,146
JBrowse link
G Cflar CASP8 and FADD-like apoptosis regulator decreases expression
increases degradation
multiple interactions
ISO sorafenib results in decreased expression of CFLAR protein
sorafenib results in increased degradation of CFLAR protein
[sorafenib co-treated with TNFSF10 protein] results in decreased expression of CFLAR protein; [sorafenib results in decreased expression of CFLAR protein] which results in increased susceptibility to TNFSF10 protein; [sorafenib results in increased degradation of CFLAR protein] which results in increased susceptibility to TNFSF10 protein
CTD PMID:17909059, PMID:20071162 NCBI chr 9:65,534,608...65,586,395
Ensembl chr 9:65,534,704...65,587,251
JBrowse link
G Col1a1 collagen type I alpha 1 chain multiple interactions
decreases expression
ISO
EXP
sorafenib inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 protein]
sorafenib results in decreased expression of COL1A1 mRNA
CTD PMID:21360571, PMID:24321339 NCBI chr10:82,745,801...82,762,790
Ensembl chr10:82,745,801...82,762,789
JBrowse link
G Col3a1 collagen type III alpha 1 chain multiple interactions ISO sorafenib inhibits the reaction [TGFB1 protein results in increased expression of COL3A1 protein] CTD PMID:21360571 NCBI chr 9:52,023,295...52,059,221
Ensembl chr 9:52,023,295...52,059,217
JBrowse link
G Col4a1 collagen type IV alpha 1 chain multiple interactions ISO sorafenib inhibits the reaction [TGFB1 protein results in increased expression of COL4A1 protein] CTD PMID:21360571 NCBI chr16:83,522,162...83,632,153
Ensembl chr16:83,522,162...83,632,153
JBrowse link
G Crkl CRK like proto-oncogene, adaptor protein multiple interactions
decreases phosphorylation
ISO sorafenib inhibits the reaction [[ABL1 protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein]; sorafenib inhibits the reaction [[BCR protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein]
sorafenib results in decreased phosphorylation of CRKL protein
CTD PMID:19366808 NCBI chr11:87,338,606...87,356,644
Ensembl chr11:87,778,312...87,815,043
JBrowse link
G Ctnnb1 catenin beta 1 multiple interactions ISO sorafenib promotes the reaction [destruxin B results in decreased expression of CTNNB1 protein] CTD PMID:24434019 NCBI chr 8:129,601,511...129,628,378
Ensembl chr 8:129,617,812...129,627,372
JBrowse link
G Cycs cytochrome c, somatic affects localization ISO sorafenib affects the localization of CYCS protein CTD PMID:16007148 NCBI chr 4:80,331,226...80,333,326
Ensembl chr 4:80,331,227...80,333,326
JBrowse link
G Cyld CYLD lysine 63 deubiquitinase increases expression ISO [sorafenib results in increased expression of CYLD protein] which results in increased expression of NFKBIA protein; sorafenib results in increased expression of CYLD mRNA; sorafenib results in increased expression of CYLD protein CTD PMID:21109933 NCBI chr19:19,264,984...19,323,817
Ensembl chr19:19,265,164...19,315,357
JBrowse link
G Ddit3 DNA-damage inducible transcript 3 increases expression ISO [sorafenib results in increased expression of ATF4 protein] which results in increased expression of DDIT3 mRNA; [sorafenib results in increased expression of ATF4 protein] which results in increased expression of DDIT3 protein; sorafenib results in increased expression of DDIT3 mRNA; sorafenib results in increased expression of DDIT3 protein CTD PMID:17548474, PMID:21601561 NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
JBrowse link
G Ddit4 DNA-damage-inducible transcript 4 multiple interactions
increases expression
ISO [[[sorafenib results in increased expression of ATF4 protein] which results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein] which results in decreased expression of BIRC5 protein; [[sorafenib results in increased expression of ATF4 protein] which results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein; [[sorafenib results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein] which results in decreased expression of BIRC5 protein; [[sorafenib results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein] which results in increased susceptibility to TNFSF10 protein; [sorafenib results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein; sorafenib promotes the reaction [ATF4 protein results in increased expression of DDIT4 protein]
[sorafenib results in increased expression of ATF4 protein] which results in increased expression of DDIT4 protein; sorafenib results in increased expression of DDIT4 protein
CTD PMID:21601561 NCBI chr20:29,509,283...29,511,382
Ensembl chr20:29,509,289...29,511,382
JBrowse link
G Diablo diablo, IAP-binding mitochondrial protein multiple interactions
affects localization
ISO 6-bromoindirubin-3'-oxime promotes the reaction [sorafenib affects the localization of DIABLO protein]; [sorafenib co-treated with TNFSF10 protein] affects the localization of DIABLO protein; GSK3B inhibits the reaction [sorafenib affects the localization of DIABLO protein]
Sorafenib affects the localization of DIABLO protein
CTD PMID:17909059, PMID:17991738 NCBI chr12:38,490,230...38,503,344
Ensembl chr12:38,490,230...38,503,330
JBrowse link
G Dok1 docking protein 1 decreases phosphorylation ISO sorafenib results in decreased phosphorylation of DOK1 protein CTD PMID:19366808 NCBI chr 4:113,864,211...113,866,695
Ensembl chr 4:113,864,215...113,866,674
JBrowse link
G Egf epidermal growth factor multiple interactions ISO [sorafenib co-treated with PI103] inhibits the reaction [EGF protein results in increased phosphorylation of MAP2K1 protein]; [sorafenib co-treated with PI103] inhibits the reaction [EGF protein results in increased phosphorylation of MAP2K2 protein]; [sorafenib co-treated with PI103] inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; [sorafenib co-treated with PI103] inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; [sorafenib co-treated with PI103] inhibits the reaction [EGF protein results in increased phosphorylation of MTOR protein]; sorafenib inhibits the reaction [EGF protein results in increased phosphorylation of MAP2K1 protein]; sorafenib inhibits the reaction [EGF protein results in increased phosphorylation of MAP2K2 protein]; sorafenib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; sorafenib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein] CTD PMID:17664273, PMID:21187475 NCBI chr 2:68,820,616...68,895,537 JBrowse link
G Egfr epidermal growth factor receptor decreases expression ISO sorafenib results in decreased expression of EGFR mRNA CTD PMID:26409325 NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
JBrowse link
G Eif2a eukaryotic translation initiation factor 2A multiple interactions
increases phosphorylation
ISO [sorafenib co-treated with vorinostat] results in increased phosphorylation of EIF2A protein; FADD protein promotes the reaction [[sorafenib co-treated with vorinostat] results in increased phosphorylation of EIF2A protein]; FAS protein promotes the reaction [[sorafenib co-treated with vorinostat] results in increased phosphorylation of EIF2A protein]
sorafenib results in increased phosphorylation of EIF2A protein
CTD PMID:17548474, PMID:18787411, PMID:19366808 NCBI chr 2:148,722,343...148,755,781
Ensembl chr 2:148,722,231...148,755,520
JBrowse link
G Eif2ak3 eukaryotic translation initiation factor 2 alpha kinase 3 multiple interactions
increases phosphorylation
ISO [sorafenib co-treated with vorinostat] promotes the reaction [FAS protein binds to EIF2AK3 protein]; [sorafenib co-treated with vorinostat] results in increased phosphorylation of EIF2AK3 protein; EIF2AK3 protein promotes the reaction [[sorafenib co-treated with vorinostat] promotes the reaction [CASP8 protein binds to ATG5 protein binds to HSPA5 protein binds to FAS protein]]; EIF2AK3 protein promotes the reaction [[sorafenib co-treated with vorinostat] promotes the reaction [FAS protein binds to FADD protein binds to CASP8 protein]]; EIF2AK3 protein promotes the reaction [[sorafenib co-treated with vorinostat] results in increased cleavage of CASP8 protein]; EIF2AK3 protein promotes the reaction [[sorafenib co-treated with vorinostat] results in increased expression of ATG5 protein]; FADD protein promotes the reaction [[sorafenib co-treated with vorinostat] results in increased phosphorylation of EIF2AK3 protein]; FAS protein promotes the reaction [[sorafenib co-treated with vorinostat] results in increased phosphorylation of EIF2AK3 protein]
sorafenib results in increased phosphorylation of EIF2AK3 protein
CTD PMID:17548474, PMID:18787411 NCBI chr 4:98,648,513...98,709,695
Ensembl chr 4:98,648,545...98,709,694
JBrowse link
G Eif4e eukaryotic translation initiation factor 4E multiple interactions
decreases phosphorylation
ISO [sorafenib results in decreased phosphorylation of EIF4E protein] which results in decreased expression of MCL1; sorafenib inhibits the reaction [MKNK1 protein results in increased phosphorylation of EIF4E protein] CTD PMID:16109713, PMID:21750559 NCBI chr 2:243,819,616...243,853,987
Ensembl chr 2:243,820,661...243,852,631
JBrowse link
G Eif4ebp1 eukaryotic translation initiation factor 4E binding protein 1 multiple interactions
increases phosphorylation
decreases phosphorylation
ISO
EXP
[2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine co-treated with sorafenib] results in decreased phosphorylation of EIF4EBP1 protein; arsenic trioxide inhibits the reaction [sorafenib results in increased phosphorylation of EIF4EBP1 protein]
sorafenib affects the reaction [TSC2 protein mutant form results in increased expression of EIF4EBP1 protein modified form]
Sorafenib results in decreased phosphorylation of EIF4EBP1 protein
CTD PMID:16255777, PMID:20054642, PMID:21601561, PMID:21813464, PMID:21858812, PMID:23036488, PMID:25416439 NCBI chr16:68,954,860...68,968,248
Ensembl chr16:68,954,875...68,968,248
JBrowse link
G Fadd Fas associated via death domain multiple interactions ISO [sorafenib co-treated with vorinostat] promotes the reaction [CASP8 protein binds to FAS protein binds to FADD protein]; EIF2AK3 protein promotes the reaction [[sorafenib co-treated with vorinostat] promotes the reaction [FAS protein binds to FADD protein binds to CASP8 protein]]; FADD protein promotes the reaction [[sorafenib co-treated with vorinostat] promotes the reaction [CASP8 protein binds to ATG5 protein binds to HSPA5 protein binds to FAS protein]]; FADD protein promotes the reaction [[sorafenib co-treated with vorinostat] results in decreased expression of ATG5 protein]; FADD protein promotes the reaction [[sorafenib co-treated with vorinostat] results in increased phosphorylation of EIF2A protein]; FADD protein promotes the reaction [[sorafenib co-treated with vorinostat] results in increased phosphorylation of EIF2AK3 protein] CTD PMID:18787411 NCBI chr 1:217,746,176...217,748,581
Ensembl chr 1:217,742,929...217,748,628
JBrowse link
G Fas Fas cell surface death receptor multiple interactions ISO [sorafenib co-treated with vorinostat] promotes the reaction [CASP8 protein binds to FAS protein binds to FADD protein]; [sorafenib co-treated with vorinostat] promotes the reaction [FAS protein binds to CASP8 protein binds to ATG5 protein binds to HSPA5 protein]; [sorafenib co-treated with vorinostat] promotes the reaction [FAS protein binds to EIF2AK3 protein]; [vorinostat co-treated with sorafenib] affects the localization of FAS protein; [vorinostat co-treated with sorafenib] results in increased activity of FAS protein; EIF2AK3 protein promotes the reaction [[sorafenib co-treated with vorinostat] promotes the reaction [CASP8 protein binds to ATG5 protein binds to HSPA5 protein binds to FAS protein]]; EIF2AK3 protein promotes the reaction [[sorafenib co-treated with vorinostat] promotes the reaction [FAS protein binds to FADD protein binds to CASP8 protein]]; FADD protein promotes the reaction [[sorafenib co-treated with vorinostat] promotes the reaction [CASP8 protein binds to ATG5 protein binds to HSPA5 protein binds to FAS protein]]; FAS protein promotes the reaction [[sorafenib co-treated with vorinostat] results in decreased expression of ATG5 protein]; FAS protein promotes the reaction [[sorafenib co-treated with vorinostat] results in increased phosphorylation of EIF2A protein]; FAS protein promotes the reaction [[sorafenib co-treated with vorinostat] results in increased phosphorylation of EIF2AK3 protein]; fumonisin B1 inhibits the reaction [[sorafenib co-treated with vorinostat] affects the localization of and results in increased activity of FAS protein]; SMPD1 protein promotes the reaction [[vorinostat co-treated with sorafenib] affects the localization of FAS protein]; thermozymocidin inhibits the reaction [[sorafenib co-treated with vorinostat] affects the localization of and results in increased activity of FAS protein] CTD PMID:18787411 NCBI chr 1:252,589,785...252,624,790
Ensembl chr 1:252,589,785...252,624,790
JBrowse link
G Faslg Fas ligand multiple interactions ISO [sorafenib co-treated with Vitamin K 1] results in increased expression of FASLG protein; pyrazolanthrone inhibits the reaction [[sorafenib co-treated with Vitamin K 1] results in increased expression of FASLG protein] CTD PMID:20301194 NCBI chr13:79,696,811...79,717,581
Ensembl chr13:79,698,445...79,705,705
JBrowse link
G Flt3 Fms related receptor tyrosine kinase 3 increases response to substance
decreases phosphorylation
multiple interactions
decreases activity
ISO FLT3 protein results in increased susceptibility to sorafenib
sorafenib results in decreased phosphorylation of FLT3 protein mutant form
[sorafenib results in decreased activity of FLT3 protein mutant form] which results in decreased phosphorylation of FLT3 protein mutant form; [sorafenib results in decreased activity of FLT3 protein mutant form] which results in decreased phosphorylation of MAPK1 protein; [sorafenib results in decreased activity of FLT3 protein mutant form] which results in decreased phosphorylation of MAPK3 protein; [sorafenib results in decreased activity of FLT3 protein] which results in decreased phosphorylation of FLT3 protein; [sorafenib results in decreased activity of FLT3 protein] which results in decreased phosphorylation of MAPK1 protein; [sorafenib results in decreased activity of FLT3 protein] which results in decreased phosphorylation of MAPK3 protein; sorafenib inhibits the reaction [FLT3 protein mutant form results in increased phosphorylation of FLT3 protein mutant form]
sorafenib results in decreased activity of FLT3 protein; sorafenib results in decreased activity of FLT3 protein mutant form
CTD PMID:17205056, PMID:17229632, PMID:21482694, PMID:22409268, PMID:23036488 NCBI chr12:9,360,439...9,437,004
Ensembl chr12:9,360,672...9,436,570
JBrowse link
G Fn1 fibronectin 1 multiple interactions ISO sorafenib inhibits the reaction [TGFB1 protein results in increased expression of FN1 protein] CTD PMID:21360571 NCBI chr 9:78,900,111...78,969,018
Ensembl chr 9:78,900,103...78,969,078
JBrowse link
G Gadd45b growth arrest and DNA-damage-inducible, beta multiple interactions
increases expression
increases response to substance
ISO pyrazolanthrone inhibits the reaction [sorafenib results in increased expression of GADD45B mRNA]; pyrazolanthrone inhibits the reaction [sorafenib results in increased expression of GADD45B protein]; sorafenib promotes the reaction [JUN protein binds to GADD45B promoter]; sorafenib results in increased expression of and results in increased localization of GADD45B protein
GADD45B protein results in increased susceptibility to sorafenib
CTD PMID:21062976 NCBI chr 7:11,646,283...11,648,338
Ensembl chr 7:11,646,269...11,648,322
JBrowse link
G Gadd45g growth arrest and DNA-damage-inducible, gamma decreases response to substance
increases expression
multiple interactions
ISO GADD45G mutant form results in decreased susceptibility to sorafenib
sorafenib results in increased expression of GADD45G mRNA; sorafenib results in increased expression of GADD45G protein
sorafenib promotes the reaction [CEBPD protein binds to GADD45G promoter]
CTD PMID:26172295 NCBI chr17:13,391,474...13,393,219
Ensembl chr17:13,391,467...13,393,243
JBrowse link
G Gpt glutamic--pyruvic transaminase multiple interactions
increases secretion
ISO Sorafenib inhibits the reaction [Diethylnitrosamine results in increased activity of GPT protein]
Sorafenib results in increased secretion of GPT protein
CTD PMID:29655783, PMID:29859236 NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
JBrowse link
G Grb2 growth factor receptor bound protein 2 decreases expression ISO sorafenib results in decreased expression of GRB2 mRNA CTD PMID:26409325 NCBI chr10:104,193,953...104,263,071
Ensembl chr10:104,193,955...104,263,071
JBrowse link
G Gsk3b glycogen synthase kinase 3 beta multiple interactions
increases phosphorylation
ISO arsenic trioxide inhibits the reaction [sorafenib results in increased phosphorylation of GSK3B protein]; GSK3B inhibits the reaction [sorafenib affects the localization of AIFM1 protein]; GSK3B inhibits the reaction [sorafenib affects the localization of DIABLO protein]; sorafenib inhibits the reaction [arsenic trioxide results in decreased phosphorylation of GSK3B protein]; sorafenib promotes the reaction [GSK3B protein results in increased phosphorylation of MYC protein]; sorafenib promotes the reaction [GSK3B protein results in increased phosphorylation of TP53 protein]; sorafenib results in decreased phosphorylation of and results in increased activity of GSK3B protein CTD PMID:17991738, PMID:25416439 NCBI chr11:65,060,884...65,208,842
Ensembl chr11:65,066,235...65,209,268
JBrowse link
G Hdac6 histone deacetylase 6 decreases expression ISO sorafenib results in decreased expression of HDAC6 mRNA CTD PMID:26409325 NCBI chr  X:15,295,372...15,316,673
Ensembl chr  X:15,295,473...15,316,671
JBrowse link
G Hgf hepatocyte growth factor decreases response to substance
multiple interactions
ISO HGF protein results in decreased susceptibility to Sorafenib
Plant Extracts inhibits the reaction [HGF protein results in decreased susceptibility to Sorafenib]
CTD PMID:32522589 NCBI chr 4:15,435,460...15,505,377
Ensembl chr 4:15,433,295...15,505,362
JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha decreases expression ISO sorafenib results in decreased expression of HIF1A mRNA CTD PMID:26409325 NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 multiple interactions ISO [sorafenib co-treated with vorinostat] promotes the reaction [FAS protein binds to CASP8 protein binds to ATG5 protein binds to HSPA5 protein]; EIF2AK3 protein promotes the reaction [[sorafenib co-treated with vorinostat] promotes the reaction [CASP8 protein binds to ATG5 protein binds to HSPA5 protein binds to FAS protein]]; FADD protein promotes the reaction [[sorafenib co-treated with vorinostat] promotes the reaction [CASP8 protein binds to ATG5 protein binds to HSPA5 protein binds to FAS protein]] CTD PMID:18787411 NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
JBrowse link
G Igf1 insulin-like growth factor 1 multiple interactions ISO sorafenib inhibits the reaction [IGF1 protein results in increased expression of BIRC5 protein] CTD PMID:21601561 NCBI chr 7:28,412,123...28,491,815
Ensembl chr 7:28,412,198...28,486,609
JBrowse link
G Igf1r insulin-like growth factor 1 receptor decreases expression ISO sorafenib results in decreased expression of IGF1R mRNA CTD PMID:26409325 NCBI chr 1:128,924,921...129,213,816
Ensembl chr 1:128,924,966...129,206,516
JBrowse link
G Irf5 interferon regulatory factor 5 increases expression ISO sorafenib results in increased expression of IRF5 mRNA CTD PMID:26409325 NCBI chr 4:56,804,477...56,816,271
Ensembl chr 4:56,805,132...56,820,543
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions
increases expression
ISO [Bortezomib co-treated with sorafenib] results in increased phosphorylation of JUN protein; [sorafenib co-treated with Vitamin K 1] results in increased phosphorylation of JUN protein; pyrazolanthrone inhibits the reaction [[sorafenib co-treated with Vitamin K 1] results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [sorafenib results in increased expression of JUN mRNA]; pyrazolanthrone inhibits the reaction [sorafenib results in increased expression of JUN protein]; sorafenib promotes the reaction [JUN protein binds to GADD45B promoter]; sorafenib results in increased expression of and results in increased phosphorylation of and results in increased localization of JUN protein CTD PMID:16985072, PMID:20301194, PMID:21062976 NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
JBrowse link
G Kcnh2 potassium voltage-gated channel subfamily H member 2 decreases activity ISO sorafenib results in decreased activity of KCNH2 protein CTD PMID:28551711 NCBI chr 4:7,355,066...7,387,282
Ensembl chr 4:7,355,574...7,387,253
JBrowse link
G Kdr kinase insert domain receptor multiple interactions
decreases phosphorylation
ISO [Bortezomib co-treated with sorafenib] results in decreased phosphorylation of KDR protein
sorafenib results in decreased phosphorylation of KDR protein
CTD PMID:16985072, PMID:19139124 NCBI chr14:34,727,677...34,787,127
Ensembl chr14:34,727,623...34,787,183
JBrowse link
G Kit KIT proto-oncogene receptor tyrosine kinase decreases phosphorylation ISO sorafenib results in decreased phosphorylation of KIT protein CTD PMID:19139124 NCBI chr14:35,072,131...35,149,638
Ensembl chr14:35,072,108...35,149,610
JBrowse link
G Lck LCK proto-oncogene, Src family tyrosine kinase decreases phosphorylation ISO sorafenib results in decreased phosphorylation of LCK protein CTD PMID:21293487 NCBI chr 5:147,750,976...147,779,627
Ensembl chr 5:147,750,973...147,761,983
JBrowse link
G Map2k1 mitogen activated protein kinase kinase 1 multiple interactions
decreases phosphorylation
ISO
EXP
[MAP2K1 protein results in increased phosphorylation of MAPK1 protein] which results in decreased susceptibility to sorafenib; [MAP2K1 protein results in increased phosphorylation of MAPK3 protein] which results in decreased susceptibility to sorafenib; [sorafenib co-treated with PI103] inhibits the reaction [EGF protein results in increased phosphorylation of MAP2K1 protein]; sorafenib inhibits the reaction [EGF protein results in increased phosphorylation of MAP2K1 protein]
sorafenib results in decreased phosphorylation of MAP2K1 protein
CTD PMID:17341847, PMID:18200035, PMID:19139124, PMID:20117835, PMID:21187475 NCBI chr 8:69,134,218...69,722,573
Ensembl chr 8:69,134,223...69,164,758
JBrowse link
G Map2k2 mitogen activated protein kinase kinase 2 multiple interactions
decreases phosphorylation
ISO
EXP
[sorafenib co-treated with PI103] inhibits the reaction [EGF protein results in increased phosphorylation of MAP2K2 protein]; sorafenib inhibits the reaction [EGF protein results in increased phosphorylation of MAP2K2 protein]
sorafenib results in decreased phosphorylation of MAP2K2 protein
CTD PMID:17341847, PMID:18200035, PMID:21187475 NCBI chr 7:11,458,971...11,478,520
Ensembl chr 7:11,458,967...11,478,489
JBrowse link
G Map2k4 mitogen activated protein kinase kinase 4 multiple interactions
decreases phosphorylation
ISO licochalcone A promotes the reaction [Sorafenib results in decreased phosphorylation of MAP2K4 protein]; Sorafenib promotes the reaction [licochalcone A results in decreased phosphorylation of MAP2K4 protein] CTD PMID:30187994 NCBI chr10:52,196,121...52,301,887
Ensembl chr10:52,196,124...52,290,657
JBrowse link
G Mapk1 mitogen activated protein kinase 1 affects phosphorylation
increases phosphorylation
decreases phosphorylation
multiple interactions
decreases expression
decreases activity
ISO
EXP
sorafenib affects the phosphorylation of MAPK1 protein
sorafenib results in increased phosphorylation of MAPK1 protein
sorafenib results in decreased phosphorylation of MAPK1 protein
Sorafenib affects the reaction [TSC2 protein mutant form results in increased expression of MAPK1 protein modified form]; Sorafenib results in decreased phosphorylation of and results in decreased activity of MAPK1 protein
sorafenib results in decreased expression of MAPK1 protein modified form
Sorafenib results in decreased phosphorylation of MAPK1 protein
sorafenib results in decreased activity of MAPK1 protein
[MAP2K1 protein results in increased phosphorylation of MAPK1 protein] which results in decreased susceptibility to sorafenib; [sorafenib co-treated with [IFNA2 protein co-treated with IFNA8 protein]] affects the phosphorylation of MAPK1 protein; [sorafenib co-treated with Cisplatin] results in decreased phosphorylation of MAPK1 protein; [sorafenib co-treated with PI103] inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; [sorafenib co-treated with rottlerin] results in decreased phosphorylation of MAPK1 protein; [sorafenib co-treated with Vitamin K 1] results in decreased phosphorylation of MAPK1 protein; [sorafenib results in decreased activity of FLT3 protein mutant form] which results in decreased phosphorylation of MAPK1 protein; [sorafenib results in decreased activity of FLT3 protein] which results in decreased phosphorylation of MAPK1 protein; sorafenib inhibits the reaction [arsenic trioxide results in increased activity of MAPK1 protein]; sorafenib inhibits the reaction [BRAF protein mutant form results in increased phosphorylation of MAPK1 protein]; sorafenib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; sorafenib results in decreased phosphorylation of and results in decreased activity of MAPK1 protein
CTD PMID:16109713, PMID:16255777, PMID:16959960, PMID:17178882, PMID:17205056, PMID:17341847, PMID:17664273, PMID:17991738, PMID:18200035, PMID:18819900, PMID:19129670, PMID:19139124, PMID:19338580, PMID:19366808, PMID:19633425, PMID:19878585, PMID:20054642, PMID:20071162, PMID:20117835, PMID:20301194, PMID:20473320, PMID:21187475, PMID:21693435, PMID:21813464, PMID:21858812, PMID:22963400, PMID:26333016 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk14 mitogen activated protein kinase 14 decreases expression ISO sorafenib results in decreased expression of MAPK14 protein modified form CTD PMID:16985072 NCBI chr20:5,933,290...5,995,137
Ensembl chr20:5,933,303...5,995,137
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
increases phosphorylation
decreases expression
decreases phosphorylation
decreases activity
affects phosphorylation
ISO
EXP
[MAP2K1 protein results in increased phosphorylation of MAPK3 protein] which results in decreased susceptibility to sorafenib; [sorafenib co-treated with [IFNA2 protein co-treated with IFNA8 protein]] affects the phosphorylation of MAPK3 protein; [sorafenib co-treated with Cisplatin] results in decreased phosphorylation of MAPK3 protein; [sorafenib co-treated with PI103] inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; [sorafenib co-treated with rottlerin] results in decreased phosphorylation of MAPK3 protein; [sorafenib co-treated with Vitamin K 1] results in decreased phosphorylation of MAPK3 protein; [sorafenib results in decreased activity of FLT3 protein mutant form] which results in decreased phosphorylation of MAPK3 protein; [sorafenib results in decreased activity of FLT3 protein] which results in decreased phosphorylation of MAPK3 protein; sorafenib inhibits the reaction [Acids results in increased phosphorylation of MAPK3 protein]; sorafenib inhibits the reaction [arsenic trioxide results in increased activity of MAPK3 protein]; sorafenib inhibits the reaction [BRAF protein mutant form results in increased phosphorylation of MAPK3 protein]; sorafenib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; sorafenib inhibits the reaction [Taurocholic Acid results in increased phosphorylation of MAPK3 protein]; sorafenib results in decreased phosphorylation of and results in decreased activity of MAPK3 protein
sorafenib results in increased phosphorylation of MAPK3 protein
sorafenib results in decreased expression of MAPK3 protein modified form
sorafenib results in decreased phosphorylation of MAPK3 protein
sorafenib affects the reaction [TSC2 protein mutant form results in increased expression of MAPK3 protein modified form]; sorafenib results in decreased phosphorylation of and results in decreased activity of MAPK3 protein
Sorafenib results in decreased phosphorylation of MAPK3 protein
sorafenib results in decreased activity of MAPK3 protein
sorafenib affects the phosphorylation of MAPK3 protein
CTD PMID:16109713, PMID:16255777, PMID:16959960, PMID:17178882, PMID:17205056, PMID:17341847, PMID:17664273, PMID:17991738, PMID:18200035, PMID:18512153, PMID:18819900, PMID:19129670, PMID:19139124, PMID:19338580, PMID:19366808, PMID:19633425, PMID:19878585, PMID:20054642, PMID:20071162, PMID:20117835, PMID:20301194, PMID:20473320, PMID:21187475, PMID:21693435, PMID:21813464, PMID:21858812, PMID:22963400, PMID:26333016 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Mapk8 mitogen-activated protein kinase 8 multiple interactions
decreases phosphorylation
ISO [Bortezomib co-treated with Sorafenib] results in increased phosphorylation of MAPK8 protein; licochalcone A promotes the reaction [Sorafenib results in decreased phosphorylation of MAPK8 protein]; Sorafenib promotes the reaction [licochalcone A results in decreased phosphorylation of MAPK8 protein] CTD PMID:16985072, PMID:30187994 NCBI chr16:9,620,854...9,709,342
Ensembl chr16:9,625,177...9,709,347
JBrowse link
G Mapk9 mitogen-activated protein kinase 9 multiple interactions
decreases phosphorylation
ISO [Bortezomib co-treated with Sorafenib] results in increased phosphorylation of MAPK9 protein; licochalcone A promotes the reaction [Sorafenib results in decreased phosphorylation of MAPK9 protein]; Sorafenib promotes the reaction [licochalcone A results in decreased phosphorylation of MAPK9 protein] CTD PMID:16985072, PMID:30187994 NCBI chr10:35,333,859...35,374,364
Ensembl chr10:35,333,859...35,374,355
JBrowse link
G Mcl1 MCL1 apoptosis regulator, BCL2 family member multiple interactions
affects response to substance
increases degradation
decreases expression
decreases response to substance
ISO [sorafenib co-treated with 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] results in decreased expression of MCL1 protein; [sorafenib co-treated with 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide] results in decreased expression of MCL1 mRNA; [sorafenib co-treated with 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide] results in decreased expression of MCL1 protein; [sorafenib co-treated with PRKN protein] results in decreased expression of MCL1 protein; [sorafenib co-treated with TNFSF10 protein] results in decreased expression of MCL1 protein; [sorafenib results in decreased phosphorylation of EIF4E protein] which results in decreased expression of MCL1; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[sorafenib co-treated with PRKN protein] results in decreased expression of MCL1 protein]; MCL1 protein inhibits the reaction [[sorafenib co-treated with TNFSF10 protein] affects the folding of and results in increased activity of BAK1 protein]; MCL1 protein inhibits the reaction [[sorafenib co-treated with TNFSF10 protein] affects the folding of and results in increased activity of BAX protein]; MCL1 protein inhibits the reaction [sorafenib results in increased cleavage of and results in increased activity of CASP9 protein]; MCL1 protein results in decreased susceptibility to [sorafenib co-treated with 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide]; sorafenib results in increased degradation of and results in decreased expression of MCL1 protein
MCL1 protein affects the susceptibility to sorafenib
sorafenib results in increased degradation of MCL1 protein
sorafenib results in decreased expression of MCL1 protein
MCL1 protein results in decreased susceptibility to sorafenib
CTD PMID:16007148, PMID:16109713, PMID:16985072, PMID:17178882, PMID:17595328, PMID:17909059, PMID:17991738, PMID:18200035, PMID:19001435, PMID:19633425, PMID:19878585, PMID:20071162, PMID:20105315, PMID:20117835, PMID:20473320, PMID:20881478, PMID:21293487, PMID:21750559, PMID:23036488, PMID:28673964 NCBI chr 2:197,786,212...197,788,992 JBrowse link
G Mdm2 MDM2 proto-oncogene increases expression ISO sorafenib results in increased expression of MDM2 mRNA CTD PMID:26409325 NCBI chr 7:60,719,060...60,743,618
Ensembl chr 7:60,719,066...60,743,328
JBrowse link
G Mknk1 MAPK interacting serine/threonine kinase 1 multiple interactions ISO sorafenib inhibits the reaction [MKNK1 protein results in increased phosphorylation of EIF4E protein] CTD PMID:16109713 NCBI chr 5:134,691,852...134,730,887
Ensembl chr 5:134,691,881...134,730,893
JBrowse link
G Mmp2 matrix metallopeptidase 2 multiple interactions ISO Sorafenib inhibits the reaction [Diethylnitrosamine results in increased expression of MMP2 protein] CTD PMID:29859236 NCBI chr19:15,542,771...15,570,589
Ensembl chr19:15,542,765...15,570,611
JBrowse link
G Msn moesin increases phosphorylation EXP sorafenib results in increased phosphorylation of MSN protein CTD PMID:19338580 NCBI chr  X:65,226,834...65,294,192
Ensembl chr  X:65,226,748...65,295,810
JBrowse link
G Mtor mechanistic target of rapamycin kinase decreases activity
increases phosphorylation
increases expression
decreases phosphorylation
multiple interactions
decreases expression
ISO sorafenib results in decreased activity of MTOR protein
sorafenib results in increased phosphorylation of MTOR protein
sorafenib results in increased expression of MTOR protein
sorafenib results in decreased phosphorylation of MTOR protein
[2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine co-treated with sorafenib] results in decreased activity of MTOR protein; [[[sorafenib results in increased expression of ATF4 protein] which results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein] which results in decreased expression of BIRC5 protein; [[sorafenib results in increased expression of ATF4 protein] which results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein; [[sorafenib results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein] which results in decreased expression of BIRC5 protein; [[sorafenib results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein] which results in increased susceptibility to TNFSF10 protein; [sorafenib co-treated with PI103] inhibits the reaction [EGF protein results in increased phosphorylation of MTOR protein]; [sorafenib results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein; arsenic trioxide inhibits the reaction [sorafenib results in increased expression of MTOR protein]
sorafenib results in decreased expression of MTOR mRNA
CTD PMID:20054642, PMID:21187475, PMID:21601561, PMID:23036488, PMID:25416439, PMID:26409325 NCBI chr 5:165,263,813...165,373,967
Ensembl chr 5:165,263,800...165,373,967
JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor multiple interactions ISO [sorafenib co-treated with letrozole] results in decreased expression of MYC protein; sorafenib inhibits the reaction [Acids results in increased expression of MYC protein]; sorafenib inhibits the reaction [Taurocholic Acid results in increased expression of MYC protein]; sorafenib promotes the reaction [GSK3B protein results in increased phosphorylation of MYC protein] CTD PMID:17991738, PMID:18512153, PMID:20054642 NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 multiple interactions ISO Sorafenib inhibits the reaction [Diethylnitrosamine results in decreased expression of NFKB1 protein] CTD PMID:29859236 NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
JBrowse link
G Nfkbia NFKB inhibitor alpha increases expression ISO [sorafenib results in increased expression of CYLD protein] which results in increased expression of NFKBIA protein CTD PMID:21109933 NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
JBrowse link
G Nras NRAS proto-oncogene, GTPase decreases expression ISO sorafenib results in decreased expression of NRAS mRNA CTD PMID:26409325 NCBI chr 2:205,553,119...205,563,716
Ensembl chr 2:205,553,163...205,560,791
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
increases cleavage
ISO [Bortezomib co-treated with sorafenib] results in increased cleavage of PARP1 protein; [sorafenib co-treated with PRKN protein] results in increased cleavage of PARP1 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of PARP1 protein]; resveratrol promotes the reaction [sorafenib results in increased cleavage of PARP1 protein] CTD PMID:16985072, PMID:20054642, PMID:26911335, PMID:28673964 NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
JBrowse link
G Pdgfra platelet derived growth factor receptor alpha decreases phosphorylation ISO sorafenib results in decreased phosphorylation of PDGFRA protein mutant form CTD PMID:21482694 NCBI chr14:35,527,926...35,581,130
Ensembl chr14:35,527,927...35,581,031
JBrowse link
G Pdgfrb platelet derived growth factor receptor beta multiple interactions
decreases expression
decreases phosphorylation
decreases activity
ISO
EXP
[Bortezomib co-treated with sorafenib] results in decreased phosphorylation of PDGFRB protein
sorafenib results in decreased phosphorylation of and results in decreased activity of PDGFRB protein
sorafenib results in decreased expression of PDGFRB mRNA
sorafenib results in decreased phosphorylation of PDGFRB protein
sorafenib results in decreased activity of PDGFRB protein mutant form
CTD PMID:16985072, PMID:17229632, PMID:19139124, PMID:19338580 NCBI chr18:56,364,586...56,406,381
Ensembl chr18:56,364,620...56,406,381
JBrowse link
G Pik3c2a phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 alpha decreases expression ISO sorafenib results in decreased expression of PIK3C2A mRNA CTD PMID:26409325 NCBI chr 1:185,210,922...185,326,314
Ensembl chr 1:185,210,922...185,326,314
JBrowse link
G Pik3ca phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha decreases expression ISO sorafenib results in decreased expression of PIK3CA mRNA CTD PMID:26409325 NCBI chr 2:118,831,350...118,861,456
Ensembl chr 2:118,831,350...118,861,454
JBrowse link
G Pim1 Pim-1 proto-oncogene, serine/threonine kinase multiple interactions ISO [2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine co-treated with sorafenib co-treated with Oxygen deficiency] results in decreased expression of PIM1 protein; [sorafenib co-treated with 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] inhibits the reaction [Oxygen deficiency results in increased expression of PIM1 protein]; [sorafenib co-treated with Oxygen deficiency] results in decreased expression of PIM1 protein; sorafenib inhibits the reaction [Oxygen deficiency results in increased expression of PIM1 protein] CTD PMID:23036488 NCBI chr20:8,165,423...8,169,557
Ensembl chr20:8,165,307...8,169,555
JBrowse link
G Pink1 PTEN induced kinase 1 multiple interactions
increases expression
affects response to substance
ISO [sorafenib co-treated with PRKN protein] results in increased expression of PINK1 protein; PINK1 protein affects the reaction [sorafenib affects the localization of PRKN protein]
sorafenib results in increased expression of PINK1 protein
PINK1 protein affects the susceptibility to sorafenib
CTD PMID:28673964 NCBI chr 5:156,677,146...156,689,258
Ensembl chr 5:156,677,146...156,689,415
JBrowse link
G Plau plasminogen activator, urokinase decreases expression
multiple interactions
ISO Sorafenib results in decreased expression of PLAU protein
licochalcone A promotes the reaction [Sorafenib results in decreased expression of PLAU protein]; Sorafenib promotes the reaction [licochalcone A results in decreased expression of PLAU protein]
CTD PMID:30187994 NCBI chr15:3,644,296...3,650,765
Ensembl chr15:3,644,769...3,650,819
JBrowse link
G Plk2 polo-like kinase 2 increases expression ISO sorafenib results in increased expression of PLK2 mRNA CTD PMID:26409325 NCBI chr 2:41,911,143...41,916,901
Ensembl chr 2:41,911,131...41,916,901
JBrowse link
G Plk3 polo-like kinase 3 increases expression ISO sorafenib results in increased expression of PLK3 mRNA CTD PMID:26409325 NCBI chr 5:135,997,725...136,002,900
Ensembl chr 5:135,997,725...136,002,900
JBrowse link
G Pmaip1 phorbol-12-myristate-13-acetate-induced protein 1 multiple interactions
decreases expression
ISO 6-bromoindirubin-3'-oxime inhibits the reaction [sorafenib results in decreased expression of PMAIP1 protein] CTD PMID:17991738 NCBI chr18:62,159,128...62,179,635
Ensembl chr18:62,174,670...62,181,102
JBrowse link
G Ppp1r15a protein phosphatase 1, regulatory subunit 15A increases expression ISO sorafenib results in increased expression of PPP1R15A protein CTD PMID:17548474 NCBI chr 1:101,511,899...101,515,043
Ensembl chr 1:101,511,901...101,514,974
JBrowse link
G Prkca protein kinase C, alpha decreases expression ISO sorafenib results in decreased expression of PRKCA mRNA CTD PMID:26409325 NCBI chr10:96,186,509...96,585,168
Ensembl chr10:96,191,133...96,584,947
JBrowse link
G Prkn parkin RBR E3 ubiquitin protein ligase increases ubiquitination
affects response to substance
multiple interactions
affects localization
ISO sorafenib results in increased ubiquitination of PRKN protein
PRKN protein affects the susceptibility to sorafenib
[sorafenib co-treated with PRKN protein] results in decreased expression of CASP3 protein; [sorafenib co-treated with PRKN protein] results in decreased expression of MCL1 protein; [sorafenib co-treated with PRKN protein] results in increased cleavage of PARP1 protein; [sorafenib co-treated with PRKN protein] results in increased expression of PINK1 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[sorafenib co-treated with PRKN protein] results in decreased expression of MCL1 protein]; PINK1 protein affects the reaction [sorafenib affects the localization of PRKN protein]
CTD PMID:28673964 NCBI chr 1:48,880,015...50,069,998 JBrowse link
G Raf1 Raf-1 proto-oncogene, serine/threonine kinase decreases activity ISO sorafenib results in decreased activity of RAF1 protein CTD PMID:19139124, PMID:21531053 NCBI chr 4:147,532,040...147,592,769
Ensembl chr 4:147,532,042...147,592,699
JBrowse link
G Rb1 RB transcriptional corepressor 1 multiple interactions
decreases expression
decreases phosphorylation
ISO [sorafenib co-treated with letrozole] results in decreased expression of RB1 protein
sorafenib results in decreased expression of RB1 protein
sorafenib results in decreased phosphorylation of RB1 protein
CTD PMID:17909054, PMID:19633425, PMID:20054642 NCBI chr15:55,081,582...55,209,060
Ensembl chr15:55,083,140...55,209,342
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO Sorafenib inhibits the reaction [Diethylnitrosamine results in increased phosphorylation of RELA protein] CTD PMID:29859236 NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
JBrowse link
G Ret ret proto-oncogene decreases activity
increases degradation
ISO Sorafenib results in decreased activity of RET protein; Sorafenib results in decreased activity of RET protein mutant form
sorafenib results in increased degradation of RET protein
CTD PMID:17664273 NCBI chr 4:150,202,170...150,249,196
Ensembl chr 4:150,202,058...150,244,372
JBrowse link
G Rock1 Rho-associated coiled-coil containing protein kinase 1 decreases expression
increases expression
EXP sorafenib results in decreased expression of ROCK1 mRNA; sorafenib results in decreased expression of ROCK1 protein
sorafenib results in increased expression of ROCK1 protein
CTD PMID:19338580 NCBI chr18:1,273,490...1,390,790
Ensembl chr18:1,273,453...1,390,190
JBrowse link
G Rps6 ribosomal protein S6 decreases phosphorylation
multiple interactions
ISO sorafenib results in decreased phosphorylation of RPS6 protein
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [sorafenib results in decreased phosphorylation of RPS6 protein]
CTD PMID:23036488 NCBI chr 5:105,197,821...105,200,681
Ensembl chr 5:105,197,857...105,200,148
JBrowse link
G Rps6kb1 ribosomal protein S6 kinase B1 multiple interactions
decreases phosphorylation
increases phosphorylation
ISO arsenic trioxide inhibits the reaction [sorafenib results in increased phosphorylation of RPS6KB1 protein]
Sorafenib results in decreased phosphorylation of RPS6KB1 protein
CTD PMID:21858812, PMID:25416439 NCBI chr10:73,824,200...73,865,503
Ensembl chr10:73,824,202...73,865,364
JBrowse link
G Serpinh1 serpin family H member 1 decreases expression EXP sorafenib results in decreased expression of SERPINH1 mRNA CTD PMID:24321339 NCBI chr 1:164,301,010...164,308,306
Ensembl chr 1:164,301,010...164,308,317
JBrowse link
G Sesn2 sestrin 2 increases expression ISO Sorafenib results in increased expression of SESN2 protein CTD PMID:31323261 NCBI chr 5:150,684,891...150,703,846
Ensembl chr 5:150,684,133...150,704,117
JBrowse link
G Slc13a5 solute carrier family 13 member 5 decreases response to substance ISO SLC13A5 protein results in decreased susceptibility to Sorafenib CTD PMID:32634519 NCBI chr10:58,806,581...58,835,549
Ensembl chr10:58,810,058...58,834,538
JBrowse link
G Smad2 SMAD family member 2 affects localization
multiple interactions
ISO sorafenib affects the localization of SMAD2 protein
sorafenib inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]
CTD PMID:21360571 NCBI chr18:72,550,107...72,612,078
Ensembl chr18:72,550,219...72,612,078
JBrowse link
G Smad3 SMAD family member 3 affects localization
multiple interactions
ISO sorafenib affects the localization of SMAD3 protein
sorafenib inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD3 protein]
CTD PMID:21360571 NCBI chr 8:68,569,530...68,678,349
Ensembl chr 8:68,569,530...68,678,349
JBrowse link
G Smad7 SMAD family member 7 decreases expression ISO sorafenib results in decreased expression of SMAD7 mRNA CTD PMID:21360571 NCBI chr18:71,395,830...71,424,164
Ensembl chr18:71,395,830...71,424,157
JBrowse link
G Smpd1 sphingomyelin phosphodiesterase 1 multiple interactions ISO [vorinostat co-treated with sorafenib] promotes the reaction [SMPD1 protein results in increased abundance of Ceramides]; SMPD1 protein promotes the reaction [[vorinostat co-treated with sorafenib] affects the localization of FAS protein] CTD PMID:18787411 NCBI chr 1:170,383,682...170,387,525
Ensembl chr 1:170,383,682...170,387,524
JBrowse link
G Snai1 snail family transcriptional repressor 1 multiple interactions ISO sorafenib inhibits the reaction [TGFB1 protein results in increased expression of SNAI1 mRNA]; sorafenib inhibits the reaction [TGFB1 protein results in increased expression of SNAI1 protein] CTD PMID:21360571 NCBI chr 3:164,274,710...164,279,199
Ensembl chr 3:164,274,710...164,279,378
JBrowse link
G Snai2 snail family transcriptional repressor 2 multiple interactions
decreases expression
ISO destruxin B promotes the reaction [sorafenib results in decreased expression of SNAI2 protein]; sorafenib promotes the reaction [destruxin B results in decreased expression of SNAI2 protein] CTD PMID:24434019 NCBI chr11:90,404,421...90,406,730
Ensembl chr11:90,403,333...90,406,797
JBrowse link
G Sox17 SRY-box transcription factor 17 decreases localization ISO sorafenib results in decreased localization of SOX17 protein CTD PMID:24154490 NCBI chr 5:14,890,318...14,895,907
Ensembl chr 5:14,890,408...14,895,907
JBrowse link
G Sqstm1 sequestosome 1 multiple interactions
decreases expression
ISO bafilomycin A1 inhibits the reaction [Sorafenib results in decreased expression of SQSTM1 protein]; Chloroquine inhibits the reaction [Sorafenib results in decreased expression of SQSTM1 protein] CTD PMID:21858812 NCBI chr10:35,704,728...35,716,316
Ensembl chr10:35,704,730...35,716,294
JBrowse link
G Src SRC proto-oncogene, non-receptor tyrosine kinase multiple interactions
decreases activity
ISO sorafenib inhibits the reaction [SRC protein results in increased phosphorylation of STAT3 protein]
sorafenib results in decreased activity of SRC protein
CTD PMID:20881478 NCBI chr 3:153,547,807...153,595,643
Ensembl chr 3:153,580,861...153,595,642
JBrowse link
G Stat3 signal transducer and activator of transcription 3 multiple interactions
affects localization
decreases phosphorylation
ISO resveratrol promotes the reaction [sorafenib results in decreased phosphorylation of STAT3 protein]; sorafenib inhibits the reaction [Acids results in increased phosphorylation of STAT3 protein]; sorafenib inhibits the reaction [SRC protein results in increased phosphorylation of STAT3 protein]; sorafenib inhibits the reaction [Taurocholic Acid results in increased phosphorylation of STAT3 protein]; sorafenib inhibits the reaction [TGFB1 protein results in increased phosphorylation of STAT3 protein]; sorafenib results in decreased phosphorylation of and results in decreased activity of STAT3 protein
sorafenib affects the localization of STAT3 protein
sorafenib analog results in decreased phosphorylation of STAT3 protein; sorafenib results in decreased phosphorylation of STAT3 protein
CTD PMID:18512153, PMID:19001435, PMID:20881478, PMID:21360571, PMID:21531053, PMID:26911335 NCBI chr10:88,790,401...88,842,263
Ensembl chr10:88,790,408...88,842,233
JBrowse link
G Stat5a signal transducer and activator of transcription 5A decreases phosphorylation
multiple interactions
decreases activity
ISO sorafenib results in decreased phosphorylation of STAT5A protein
resveratrol promotes the reaction [sorafenib results in decreased phosphorylation of STAT5A protein]
sorafenib results in decreased activity of STAT5A protein
CTD PMID:17595328, PMID:23036488, PMID:26911335 NCBI chr10:88,764,732...88,789,060
Ensembl chr10:88,764,732...88,789,057
JBrowse link
G Stat5b signal transducer and activator of transcription 5B multiple interactions ISO resveratrol promotes the reaction [sorafenib results in decreased phosphorylation of STAT5B protein] CTD PMID:26911335 NCBI chr10:88,686,207...88,712,313
Ensembl chr10:88,686,207...88,754,829
JBrowse link
G Stc1 stanniocalcin 1 decreases expression
multiple interactions
ISO sorafenib results in decreased expression of STC1 mRNA
STC1 affects the reaction [sorafenib results in increased abundance of Reactive Oxygen Species]
CTD PMID:25370841 NCBI chr15:50,891,137...50,901,791
Ensembl chr15:50,891,127...50,903,162
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions
decreases expression
decreases activity
ISO Sorafenib inhibits the reaction [TGFB1 protein results in decreased expression of CDH1 protein]; Sorafenib inhibits the reaction [TGFB1 protein results in decreased expression of TJP1 protein]; Sorafenib inhibits the reaction [TGFB1 protein results in increased activity of CASP3 mRNA]; Sorafenib inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 protein]; Sorafenib inhibits the reaction [TGFB1 protein results in increased expression of COL3A1 protein]; Sorafenib inhibits the reaction [TGFB1 protein results in increased expression of COL4A1 protein]; Sorafenib inhibits the reaction [TGFB1 protein results in increased expression of FN1 protein]; Sorafenib inhibits the reaction [TGFB1 protein results in increased expression of SNAI1 mRNA]; Sorafenib inhibits the reaction [TGFB1 protein results in increased expression of SNAI1 protein]; Sorafenib inhibits the reaction [TGFB1 protein results in increased expression of VIM protein]; Sorafenib inhibits the reaction [TGFB1 protein results in increased phosphorylation of STAT3 protein]
sorafenib results in decreased expression of TGFB1 mRNA
sorafenib results in decreased activity of TGFB1 protein
Sorafenib inhibits the reaction [Diethylnitrosamine results in increased expression of TGFB1 protein]; Sorafenib inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]; Sorafenib inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD3 protein]
CTD PMID:21360571, PMID:29859236 NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
JBrowse link
G Timp3 TIMP metallopeptidase inhibitor 3 decreases expression ISO sorafenib results in decreased expression of TIMP3 mRNA CTD PMID:21360571 NCBI chr 7:23,543,125...23,594,170
Ensembl chr 7:23,544,215...23,594,133
JBrowse link
G Tjp1 tight junction protein 1 multiple interactions ISO sorafenib inhibits the reaction [TGFB1 protein results in decreased expression of TJP1 protein] CTD PMID:21360571 NCBI chr 1:126,146,489...126,515,359
Ensembl chr 1:126,146,489...126,227,469
JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO Sorafenib inhibits the reaction [Diethylnitrosamine results in increased expression of TNF protein] CTD PMID:29859236 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
G Tnfsf10 TNF superfamily member 10 multiple interactions
increases response to substance
ISO [[Sorafenib results in increased expression of DDIT4 protein] which results in decreased activity of MTOR protein] which results in increased susceptibility to TNFSF10 protein; [Sorafenib co-treated with TNFSF10 protein] affects the folding of and results in increased activity of BAK1 protein; [Sorafenib co-treated with TNFSF10 protein] affects the folding of and results in increased activity of BAX protein; [Sorafenib co-treated with TNFSF10 protein] affects the localization of AIFM1 protein; [Sorafenib co-treated with TNFSF10 protein] affects the localization of BAX protein; [Sorafenib co-treated with TNFSF10 protein] affects the localization of DIABLO protein; [Sorafenib co-treated with TNFSF10 protein] promotes the reaction [CASP8 protein modified form results in increased cleavage of BID protein]; [Sorafenib co-treated with TNFSF10 protein] results in decreased expression of BCL2L1 protein; [Sorafenib co-treated with TNFSF10 protein] results in decreased expression of CFLAR protein; [Sorafenib co-treated with TNFSF10 protein] results in decreased expression of MCL1 protein; [Sorafenib co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP3 protein; [Sorafenib co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP7 protein; [Sorafenib co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP8 protein; [Sorafenib co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP9 protein; [Sorafenib co-treated with TNFSF10 protein] results in increased cleavage of BID protein; [Sorafenib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein; [Sorafenib co-treated with TNFSF10 protein] results in increased cleavage of CASP8 protein; [Sorafenib co-treated with TNFSF10 protein] results in increased cleavage of CASP9 protein; [Sorafenib co-treated with TNFSF10 protein] results in increased cleavage of XIAP protein; [Sorafenib results in decreased expression of CFLAR protein] which results in increased susceptibility to TNFSF10 protein; [Sorafenib results in increased degradation of CFLAR protein] which results in increased susceptibility to TNFSF10 protein; MCL1 protein inhibits the reaction [[Sorafenib co-treated with TNFSF10 protein] affects the folding of and results in increased activity of BAK1 protein]; MCL1 protein inhibits the reaction [[Sorafenib co-treated with TNFSF10 protein] affects the folding of and results in increased activity of BAX protein]
sorafenib results in increased susceptibility to TNFSF10 protein
CTD PMID:17909059, PMID:20071162, PMID:21601561 NCBI chr 2:113,008,008...113,026,899
Ensembl chr 2:113,007,549...113,026,899
JBrowse link
G Tp53 tumor protein p53 multiple interactions ISO sorafenib promotes the reaction [GSK3B protein results in increased phosphorylation of TP53 protein] CTD PMID:17991738 NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
JBrowse link
G Tsc2 TSC complex subunit 2 multiple interactions EXP sorafenib affects the reaction [TSC2 protein mutant form results in increased expression of EIF4EBP1 protein modified form]; sorafenib affects the reaction [TSC2 protein mutant form results in increased expression of MAPK1 protein modified form]; sorafenib affects the reaction [TSC2 protein mutant form results in increased expression of MAPK3 protein modified form]; sorafenib inhibits the reaction [TSC2 protein mutant form results in increased expression of CCND1 protein] CTD PMID:21813464 NCBI chr10:13,962,006...13,996,684
Ensembl chr10:13,961,947...13,996,584
JBrowse link
G Twist1 twist family bHLH transcription factor 1 decreases expression ISO sorafenib results in decreased expression of TWIST1 mRNA CTD PMID:21360571 NCBI chr 6:53,401,241...53,403,235
Ensembl chr 6:53,401,109...53,403,214
JBrowse link
G Txnrd1 thioredoxin reductase 1 increases expression ISO sorafenib results in increased expression of TXNRD1 mRNA CTD PMID:26409325 NCBI chr 7:26,946,124...26,984,400
Ensembl chr 7:26,946,125...26,984,400
JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions ISO Sorafenib inhibits the reaction [Diethylnitrosamine results in increased expression of VEGFA protein] CTD PMID:29859236 NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
JBrowse link
G Vim vimentin multiple interactions
decreases expression
ISO destruxin B promotes the reaction [sorafenib results in decreased expression of VIM protein]; sorafenib inhibits the reaction [TGFB1 protein results in increased expression of VIM protein]; sorafenib promotes the reaction [destruxin B results in decreased expression of VIM protein] CTD PMID:21360571, PMID:24434019 NCBI chr17:80,882,715...80,891,200
Ensembl chr17:80,882,666...80,891,212
JBrowse link
G Xbp1 X-box binding protein 1 increases splicing ISO sorafenib results in increased splicing of XBP1 mRNA CTD PMID:17548474 NCBI chr14:85,753,736...85,758,820
Ensembl chr14:85,753,760...85,758,145
JBrowse link
G Xiap X-linked inhibitor of apoptosis decreases expression
increases cleavage
multiple interactions
ISO sorafenib results in decreased expression of XIAP protein
sorafenib results in increased cleavage of XIAP protein
[sorafenib co-treated with TNFSF10 protein] results in increased cleavage of XIAP protein
CTD PMID:16109713, PMID:17909059, PMID:18200035 NCBI chr  X:128,409,425...128,455,786
Ensembl chr  X:128,409,472...128,453,000
JBrowse link
G Yap1 Yes1 associated transcriptional regulator decreases response to substance ISO YAP1 protein results in decreased susceptibility to sorafenib CTD PMID:29698666 NCBI chr 8:6,133,014...6,204,240
Ensembl chr 8:6,135,493...6,203,579
JBrowse link
G Zeb1 zinc finger E-box binding homeobox 1 decreases expression ISO sorafenib results in decreased expression of ZEB1 mRNA CTD PMID:21360571 NCBI chr17:54,656,627...54,714,920
Ensembl chr17:54,658,463...54,714,914
JBrowse link
G Zeb2 zinc finger E-box binding homeobox 2 decreases expression ISO sorafenib results in decreased expression of ZEB2 mRNA CTD PMID:21360571 NCBI chr 3:29,857,289...29,985,932
Ensembl chr 3:29,862,473...29,996,865
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19816
    chemical entity 19816
      atom 19814
        nonmetal atom 19690
          nitrogen atom 18565
            nitrogen molecular entity 18565
              organonitrogen compound 18338
                carboxamide 17158
                  pyridinecarboxamide 278
                    1-(4-bromo-2-chlorophenyl)-3-[[oxo(pyridin-4-yl)methyl]amino]thiourea 0
                    1-[(2-chlorophenyl)methyl]-2-oxo-6-(trifluoromethyl)-3-pyridinecarboxamide 0
                    1-[3-(1-\{[5-(2-phenylethyl)pyridin-3-yl]carbonyl\}piperidin-4-yl)phenyl]methanamine 0
                    1-[[oxo(3-pyridinyl)methyl]amino]-3-(4-propan-2-ylphenyl)thiourea 0
                    1-ribosyl-imidazolenicotinamide 0
                    2-(2,4-dimethylanilino)-N-(thiophen-2-ylmethyl)-3-pyridinecarboxamide 0
                    2-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-3-pyridinecarboxamide 0
                    2-(4-chloro-2-methylanilino)-3-pyridinecarboxamide 0
                    2-methylnicotinamide 0
                    2-oxo-N-(2-thiazolyl)-1H-pyridine-3-carboxamide 0
                    2-tert-butyl-N-(phenylmethyl)-4-pyridinecarboxamide 0
                    3-[(2,2-dimethylpropanoyl)amino]-N-1,3-thiazol-2-ylpyridine-2-carboxamide 0
                    5-bromo-N-(4-methyl-2-thiazolyl)-3-pyridinecarboxamide 0
                    5-bromo-N-[(2-pyridinylamino)-sulfanylidenemethyl]-3-pyridinecarboxamide 0
                    5-bromo-N-[(5-nitro-2-thiophenyl)methylideneamino]-3-pyridinecarboxamide 0
                    5-bromo-N-[[(3-methyl-2-pyridinyl)amino]-sulfanylidenemethyl]-3-pyridinecarboxamide 0
                    5-bromo-N-[[(4-methyl-2-pyridinyl)amino]-sulfanylidenemethyl]-3-pyridinecarboxamide 0
                    5-hydroxy-N-[2-[[(5-hydroxy-3-pyridinyl)-oxomethyl]amino]propyl]-3-pyridinecarboxamide 0
                    5-pentyl-N-\{[4'-(piperidin-1-ylcarbonyl)biphenyl-4-yl]methyl\}-N-[1-(pyridin-2-ylmethyl)piperidin-4-yl]pyridin-2-carboxamide 0
                    6-Methylnicotinamide 0
                    6-methyl-N-(2-pyridinylmethylideneamino)-3-pyridinecarboxamide 0
                    6-methyl-N-[(2-methyl-3-phenylprop-2-enylidene)amino]-3-pyridinecarboxamide 0
                    Boscalid Glc ac a and b 0
                    CGP-42112A 7
                    DCC-2036 0
                    LSM-10636 0
                    LSM-11859 0
                    LSM-12441 0
                    LSM-12531 0
                    LSM-42129 0
                    LSM-9039 0
                    LSM-9505 0
                    LSM-9579 0
                    Lazabemide hydrochloride 0
                    Mercapturic conjugation of Boscalid 0
                    N-(1-adamantyl)-5-hydroxy-3-pyridinecarboxamide 0
                    N-(3-\{[7-methoxy-6-(2-pyrrolidin-1-ylethoxy)quinazolin-4-yl]amino\}-4-methylphenyl)-2-morpholin-4-ylisonicotinamide 0
                    N-[(2-methyl-3-phenylprop-2-enylidene)amino]-3-pyridinecarboxamide 0
                    N-[(2R,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3R)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3R)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-2-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-(phenylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-(phenylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide 0
                    N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                    N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                    N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                    N-[(2R,3R,6R)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3R,6R)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                    N-[(2R,3R,6R)-6-[2-[(3,5-difluorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide 0
                    N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide 0
                    N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                    N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                    N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                    N-[(2R,3R,6S)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3R,6S)-6-[2-[(3,5-difluorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]pyridine-2-carboxamide 0
                    N-[(2R,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3S)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3S)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3S)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-2-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-(phenylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-2-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-(phenylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[oxo-(propan-2-ylamino)methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide 0
                    N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                    N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                    N-[(2R,3S,6R)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3S,6R)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                    N-[(2R,3S,6R)-6-[2-[(3,5-difluorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide 0
                    N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide 0
                    N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                    N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                    N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                    N-[(2R,3S,6S)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-4-pyridinecarboxamide 0
                    N-[(2R,3S,6S)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                    N-[(2R,3S,6S)-6-[2-[(3,5-difluorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide 0
                    N-[(2S)-2,3-dihydroxypropyl]-3-(2-fluoro-4-iodoanilino)-4-pyridinecarboxamide 0
                    N-[(2S,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3R)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3R)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-2-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-(phenylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-2-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-(phenylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[oxo-(propan-2-ylamino)methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide 0
                    N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                    N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                    N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                    N-[(2S,3R,6R)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3R,6R)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                    N-[(2S,3R,6R)-6-[2-[(3,5-difluorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide 0
                    N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide 0
                    N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(2-piperidin-1-ylethylamino)ethyl]-3,6-dihydro-2H-pyran-3-yl]pyridine-3-carboxamide 0
                    N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                    N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                    N-[(2S,3R,6S)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3R,6S)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                    N-[(2S,3R,6S)-6-[2-[(3,5-difluorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide 0
                    N-[(2S,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3S)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3S)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-(phenylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-2-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-(phenylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide 0
                    N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(2-piperidin-1-ylethylamino)ethyl]-3,6-dihydro-2H-pyran-3-yl]pyridine-3-carboxamide 0
                    N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                    N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                    N-[(2S,3S,6R)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]pyridine-4-carboxamide 0
                    N-[(2S,3S,6R)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                    N-[(2S,3S,6R)-6-[2-[(3,5-difluorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide 0
                    N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide 0
                    N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(2-piperidin-1-ylethylamino)ethyl]-3,6-dihydro-2H-pyran-3-yl]pyridine-3-carboxamide 0
                    N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                    N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                    N-[(2S,3S,6S)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-4-pyridinecarboxamide 0
                    N-[(2S,3S,6S)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                    N-[(2S,3S,6S)-6-[2-[(3,5-difluorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]pyridine-2-carboxamide 0
                    N-[(3,3-dimethyl-5-oxocyclohexylidene)amino]-3-pyridinecarboxamide 0
                    N-[1,1,1,3,3,3-hexafluoro-2-(2-pyridinylmethylamino)propan-2-yl]-3-pyridinecarboxamide 0
                    N-[2-(3,4-diethoxyphenyl)ethyl]-2-pyridinecarboxamide 0
                    N-[2-[2-[2-[[oxo(3-pyridinyl)methyl]amino]ethoxy]ethoxy]ethyl]-3-pyridinecarboxamide 0
                    N-[3-[(phenylmethyl)amino]propyl]-2-pyridinecarboxamide 0
                    N-[4-methyl-6-(1-oxobutylamino)-3-pyridinyl]-4-pyridinecarboxamide 0
                    N-[5-(2-chlorophenyl)-1,3,4-oxadiazol-2-yl]-3-pyridinecarboxamide 0
                    N-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]-3-pyridinecarboxamide 0
                    N-[5-[(3-methoxyphenyl)methylidene]-4-oxo-2-sulfanylidene-3-thiazolidinyl]-4-pyridinecarboxamide 0
                    N-[6-(1-oxopentylamino)-3-pyridinyl]-3-pyridinecarboxamide 0
                    N-[6-[[cyclohexyl(oxo)methyl]amino]-3-pyridinyl]-2-pyridinecarboxamide 0
                    N-[[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                    N-[[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                    N-[[(2R,3R)-8-(1-cyclopentenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(2R,3R)-8-(1-cyclopentenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(2R,3R)-8-(2-cyclopentylethynyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                    N-[[(2R,3R)-8-(2-cyclopentylethynyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                    N-[[(2R,3R)-8-bromo-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(2R,3R)-8-bromo-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                    N-[[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                    N-[[(2R,3S)-8-(1-cyclopentenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(2R,3S)-8-(1-cyclopentenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(2R,3S)-8-(2-cyclopentylethynyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                    N-[[(2R,3S)-8-(2-cyclopentylethynyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                    N-[[(2R,3S)-8-bromo-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(2R,3S)-8-bromo-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                    N-[[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                    N-[[(2S,3R)-8-(1-cyclopentenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(2S,3R)-8-(1-cyclopentenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(2S,3R)-8-(2-cyclopentylethynyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                    N-[[(2S,3R)-8-(2-cyclopentylethynyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                    N-[[(2S,3R)-8-bromo-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(2S,3R)-8-bromo-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                    N-[[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                    N-[[(2S,3S)-8-(1-cyclopentenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(2S,3S)-8-(1-cyclopentenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(2S,3S)-8-(2-cyclopentylethynyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                    N-[[(2S,3S)-8-(2-cyclopentylethynyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                    N-[[(2S,3S)-8-bromo-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(2S,3S)-8-bromo-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(4R,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(2-methylphenyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(4R,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(3-methylbut-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                    N-[[(4R,5R)-2-[(2R)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                    N-[[(4R,5R)-2-[(2R)-1-hydroxypropan-2-yl]-8-[2-(4-methoxyphenyl)ethynyl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(4R,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(2-methylphenyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(4R,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(3-methylbut-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                    N-[[(4R,5R)-2-[(2S)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                    N-[[(4R,5R)-2-[(2S)-1-hydroxypropan-2-yl]-8-[2-(4-methoxyphenyl)ethynyl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(4R,5R)-8-(3-cyanophenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                    N-[[(4R,5R)-8-(3-cyanophenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                    N-[[(4R,5R)-8-[2-(1-hydroxycyclopentyl)ethynyl]-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                    N-[[(4R,5R)-8-[2-(1-hydroxycyclopentyl)ethynyl]-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                    N-[[(4R,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(2-methylphenyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(4R,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(3-methylbut-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                    N-[[(4R,5S)-2-[(2R)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                    N-[[(4R,5S)-2-[(2R)-1-hydroxypropan-2-yl]-8-[2-(4-methoxyphenyl)ethynyl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(4R,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(2-methylphenyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(4R,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(3-methylbut-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                    N-[[(4R,5S)-2-[(2S)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                    N-[[(4R,5S)-2-[(2S)-1-hydroxypropan-2-yl]-8-[2-(4-methoxyphenyl)ethynyl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(4R,5S)-8-(3-cyanophenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                    N-[[(4R,5S)-8-(3-cyanophenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                    N-[[(4R,5S)-8-[2-(1-hydroxycyclopentyl)ethynyl]-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                    N-[[(4R,5S)-8-[2-(1-hydroxycyclopentyl)ethynyl]-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                    N-[[(4S,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(2-methylphenyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(4S,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(3-methylbut-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                    N-[[(4S,5R)-2-[(2R)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                    N-[[(4S,5R)-2-[(2R)-1-hydroxypropan-2-yl]-8-[2-(4-methoxyphenyl)ethynyl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(4S,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(2-methylphenyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(4S,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(3-methylbut-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                    N-[[(4S,5R)-2-[(2S)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                    N-[[(4S,5R)-2-[(2S)-1-hydroxypropan-2-yl]-8-[2-(4-methoxyphenyl)ethynyl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(4S,5R)-8-(1-cyclopentenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                    N-[[(4S,5R)-8-(3-cyanophenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                    N-[[(4S,5R)-8-(3-cyanophenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                    N-[[(4S,5R)-8-[2-(1-hydroxycyclopentyl)ethynyl]-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                    N-[[(4S,5R)-8-[2-(1-hydroxycyclopentyl)ethynyl]-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                    N-[[(4S,5R)-8-bromo-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                    N-[[(4S,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(2-methylphenyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(4S,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(3-methylbut-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                    N-[[(4S,5S)-2-[(2R)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                    N-[[(4S,5S)-2-[(2R)-1-hydroxypropan-2-yl]-8-[2-(4-methoxyphenyl)ethynyl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(4S,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(2-methylphenyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(4S,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(3-methylbut-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                    N-[[(4S,5S)-2-[(2S)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                    N-[[(4S,5S)-2-[(2S)-1-hydroxypropan-2-yl]-8-[2-(4-methoxyphenyl)ethynyl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                    N-[[(4S,5S)-8-(3-cyanophenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                    N-[[(4S,5S)-8-(3-cyanophenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                    N-[[(4S,5S)-8-[2-(1-hydroxycyclopentyl)ethynyl]-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                    N-[[(4S,5S)-8-[2-(1-hydroxycyclopentyl)ethynyl]-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                    N-[[3-methoxy-4-[2-(4-methylanilino)-2-oxoethoxy]phenyl]methylideneamino]-3-pyridinecarboxamide 0
                    N-[[5-(4-nitrophenyl)-2-furanyl]methylideneamino]-3-pyridinecarboxamide 0
                    N-\{4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl\}pyridine-3-carboxamide 0
                    N-hydroxy-4-pyridinecarboxamide 0
                    N-methyl-4-pyridone-3-carboxamide + 0
                    N-methyl-6-pyridone-3-carboxamide + 1
                    N-methyl-N-[5-(3-pyridinyl)-1,3,4-thiadiazol-2-yl]-3-pyridinecarboxamide 0
                    N-methylnicotinamide 2
                    N-ribosyl-4-pyridone-3-carboxamide 0
                    acetic acid 2-[[oxo(3-pyridinyl)methyl]amino]ethyl ester 0
                    boscalid + 0
                    caerulomycin I 0
                    caerulomycinamide 0
                    cyclobutrifluram 0
                    diflufenican 0
                    flonicamid 0
                    florylpicoxamid 0
                    hydroxymethylnicotinamide 0
                    isonicotinamide + 8
                    motesanib 0
                    nicorandil 18
                    nicotinamide + 135
                    nikethamide 0
                    picolinafen 0
                    picolinamide 0
                    regorafenib + 13
                    sorafenib + 156
                    tert-butyl [2-(1,3-thiazol-2-ylcarbamoyl)pyridin-3-yl]carbamate 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 19816
    subatomic particle 19814
      composite particle 19814
        hadron 19814
          baryon 19814
            nucleon 19814
              atomic nucleus 19814
                atom 19814
                  main group element atom 19702
                    p-block element atom 19702
                      carbon group element atom 19608
                        carbon atom 19597
                          organic molecular entity 19597
                            organic group 18537
                              organic divalent group 18530
                                organodiyl group 18530
                                  carbonyl group 18436
                                    carbonyl compound 18436
                                      carboxylic acid 18114
                                        carboacyl group 17372
                                          univalent carboacyl group 17372
                                            carbamoyl group 17158
                                              carboxamide 17158
                                                pyridinecarboxamide 278
                                                  1-(4-bromo-2-chlorophenyl)-3-[[oxo(pyridin-4-yl)methyl]amino]thiourea 0
                                                  1-[(2-chlorophenyl)methyl]-2-oxo-6-(trifluoromethyl)-3-pyridinecarboxamide 0
                                                  1-[3-(1-\{[5-(2-phenylethyl)pyridin-3-yl]carbonyl\}piperidin-4-yl)phenyl]methanamine 0
                                                  1-[[oxo(3-pyridinyl)methyl]amino]-3-(4-propan-2-ylphenyl)thiourea 0
                                                  1-ribosyl-imidazolenicotinamide 0
                                                  2-(2,4-dimethylanilino)-N-(thiophen-2-ylmethyl)-3-pyridinecarboxamide 0
                                                  2-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-3-pyridinecarboxamide 0
                                                  2-(4-chloro-2-methylanilino)-3-pyridinecarboxamide 0
                                                  2-methylnicotinamide 0
                                                  2-oxo-N-(2-thiazolyl)-1H-pyridine-3-carboxamide 0
                                                  2-tert-butyl-N-(phenylmethyl)-4-pyridinecarboxamide 0
                                                  3-[(2,2-dimethylpropanoyl)amino]-N-1,3-thiazol-2-ylpyridine-2-carboxamide 0
                                                  5-bromo-N-(4-methyl-2-thiazolyl)-3-pyridinecarboxamide 0
                                                  5-bromo-N-[(2-pyridinylamino)-sulfanylidenemethyl]-3-pyridinecarboxamide 0
                                                  5-bromo-N-[(5-nitro-2-thiophenyl)methylideneamino]-3-pyridinecarboxamide 0
                                                  5-bromo-N-[[(3-methyl-2-pyridinyl)amino]-sulfanylidenemethyl]-3-pyridinecarboxamide 0
                                                  5-bromo-N-[[(4-methyl-2-pyridinyl)amino]-sulfanylidenemethyl]-3-pyridinecarboxamide 0
                                                  5-hydroxy-N-[2-[[(5-hydroxy-3-pyridinyl)-oxomethyl]amino]propyl]-3-pyridinecarboxamide 0
                                                  5-pentyl-N-\{[4'-(piperidin-1-ylcarbonyl)biphenyl-4-yl]methyl\}-N-[1-(pyridin-2-ylmethyl)piperidin-4-yl]pyridin-2-carboxamide 0
                                                  6-Methylnicotinamide 0
                                                  6-methyl-N-(2-pyridinylmethylideneamino)-3-pyridinecarboxamide 0
                                                  6-methyl-N-[(2-methyl-3-phenylprop-2-enylidene)amino]-3-pyridinecarboxamide 0
                                                  Boscalid Glc ac a and b 0
                                                  CGP-42112A 7
                                                  DCC-2036 0
                                                  LSM-10636 0
                                                  LSM-11859 0
                                                  LSM-12441 0
                                                  LSM-12531 0
                                                  LSM-42129 0
                                                  LSM-9039 0
                                                  LSM-9505 0
                                                  LSM-9579 0
                                                  Lazabemide hydrochloride 0
                                                  Mercapturic conjugation of Boscalid 0
                                                  N-(1-adamantyl)-5-hydroxy-3-pyridinecarboxamide 0
                                                  N-(3-\{[7-methoxy-6-(2-pyrrolidin-1-ylethoxy)quinazolin-4-yl]amino\}-4-methylphenyl)-2-morpholin-4-ylisonicotinamide 0
                                                  N-[(2-methyl-3-phenylprop-2-enylidene)amino]-3-pyridinecarboxamide 0
                                                  N-[(2R,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3R)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3R)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-2-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-(phenylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-(phenylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide 0
                                                  N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2R,3R,6R)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3R,6R)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2R,3R,6R)-6-[2-[(3,5-difluorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide 0
                                                  N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide 0
                                                  N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2R,3R,6S)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3R,6S)-6-[2-[(3,5-difluorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]pyridine-2-carboxamide 0
                                                  N-[(2R,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3S)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3S)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3S)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-2-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-(phenylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-2-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-(phenylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[oxo-(propan-2-ylamino)methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide 0
                                                  N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2R,3S,6R)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3S,6R)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2R,3S,6R)-6-[2-[(3,5-difluorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide 0
                                                  N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide 0
                                                  N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2R,3S,6S)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-4-pyridinecarboxamide 0
                                                  N-[(2R,3S,6S)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2R,3S,6S)-6-[2-[(3,5-difluorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide 0
                                                  N-[(2S)-2,3-dihydroxypropyl]-3-(2-fluoro-4-iodoanilino)-4-pyridinecarboxamide 0
                                                  N-[(2S,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3R)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3R)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-2-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-(phenylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-2-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-(phenylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[oxo-(propan-2-ylamino)methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide 0
                                                  N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2S,3R,6R)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3R,6R)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2S,3R,6R)-6-[2-[(3,5-difluorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide 0
                                                  N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide 0
                                                  N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(2-piperidin-1-ylethylamino)ethyl]-3,6-dihydro-2H-pyran-3-yl]pyridine-3-carboxamide 0
                                                  N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2S,3R,6S)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3R,6S)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2S,3R,6S)-6-[2-[(3,5-difluorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide 0
                                                  N-[(2S,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3S)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3S)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-(phenylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-2-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-(phenylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide 0
                                                  N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(2-piperidin-1-ylethylamino)ethyl]-3,6-dihydro-2H-pyran-3-yl]pyridine-3-carboxamide 0
                                                  N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2S,3S,6R)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]pyridine-4-carboxamide 0
                                                  N-[(2S,3S,6R)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2S,3S,6R)-6-[2-[(3,5-difluorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide 0
                                                  N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(1-piperidinyl)ethyl]-3,6-dihydro-2H-pyran-3-yl]-2-pyridinecarboxamide 0
                                                  N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(2-piperidin-1-ylethylamino)ethyl]-3,6-dihydro-2H-pyran-3-yl]pyridine-3-carboxamide 0
                                                  N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2S,3S,6S)-6-[2-(cyclopropylmethylamino)-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-4-pyridinecarboxamide 0
                                                  N-[(2S,3S,6S)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-3-pyridinecarboxamide 0
                                                  N-[(2S,3S,6S)-6-[2-[(3,5-difluorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]pyridine-2-carboxamide 0
                                                  N-[(3,3-dimethyl-5-oxocyclohexylidene)amino]-3-pyridinecarboxamide 0
                                                  N-[1,1,1,3,3,3-hexafluoro-2-(2-pyridinylmethylamino)propan-2-yl]-3-pyridinecarboxamide 0
                                                  N-[2-(3,4-diethoxyphenyl)ethyl]-2-pyridinecarboxamide 0
                                                  N-[2-[2-[2-[[oxo(3-pyridinyl)methyl]amino]ethoxy]ethoxy]ethyl]-3-pyridinecarboxamide 0
                                                  N-[3-[(phenylmethyl)amino]propyl]-2-pyridinecarboxamide 0
                                                  N-[4-methyl-6-(1-oxobutylamino)-3-pyridinyl]-4-pyridinecarboxamide 0
                                                  N-[5-(2-chlorophenyl)-1,3,4-oxadiazol-2-yl]-3-pyridinecarboxamide 0
                                                  N-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]-3-pyridinecarboxamide 0
                                                  N-[5-[(3-methoxyphenyl)methylidene]-4-oxo-2-sulfanylidene-3-thiazolidinyl]-4-pyridinecarboxamide 0
                                                  N-[6-(1-oxopentylamino)-3-pyridinyl]-3-pyridinecarboxamide 0
                                                  N-[6-[[cyclohexyl(oxo)methyl]amino]-3-pyridinyl]-2-pyridinecarboxamide 0
                                                  N-[[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(2R,3R)-8-(1-cyclopentenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(2R,3R)-8-(1-cyclopentenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(2R,3R)-8-(2-cyclopentylethynyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                                                  N-[[(2R,3R)-8-(2-cyclopentylethynyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                                                  N-[[(2R,3R)-8-bromo-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(2R,3R)-8-bromo-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(2R,3S)-8-(1-cyclopentenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(2R,3S)-8-(1-cyclopentenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(2R,3S)-8-(2-cyclopentylethynyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                                                  N-[[(2R,3S)-8-(2-cyclopentylethynyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                                                  N-[[(2R,3S)-8-bromo-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(2R,3S)-8-bromo-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(2S,3R)-8-(1-cyclopentenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(2S,3R)-8-(1-cyclopentenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(2S,3R)-8-(2-cyclopentylethynyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                                                  N-[[(2S,3R)-8-(2-cyclopentylethynyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                                                  N-[[(2S,3R)-8-bromo-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(2S,3R)-8-bromo-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(2S,3S)-8-(1-cyclopentenyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(2S,3S)-8-(1-cyclopentenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(2S,3S)-8-(2-cyclopentylethynyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                                                  N-[[(2S,3S)-8-(2-cyclopentylethynyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                                                  N-[[(2S,3S)-8-bromo-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(2S,3S)-8-bromo-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(4R,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(2-methylphenyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(4R,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(3-methylbut-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                                                  N-[[(4R,5R)-2-[(2R)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(4R,5R)-2-[(2R)-1-hydroxypropan-2-yl]-8-[2-(4-methoxyphenyl)ethynyl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(4R,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(2-methylphenyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(4R,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(3-methylbut-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                                                  N-[[(4R,5R)-2-[(2S)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(4R,5R)-2-[(2S)-1-hydroxypropan-2-yl]-8-[2-(4-methoxyphenyl)ethynyl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(4R,5R)-8-(3-cyanophenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                                                  N-[[(4R,5R)-8-(3-cyanophenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                                                  N-[[(4R,5R)-8-[2-(1-hydroxycyclopentyl)ethynyl]-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(4R,5R)-8-[2-(1-hydroxycyclopentyl)ethynyl]-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(4R,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(2-methylphenyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(4R,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(3-methylbut-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                                                  N-[[(4R,5S)-2-[(2R)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(4R,5S)-2-[(2R)-1-hydroxypropan-2-yl]-8-[2-(4-methoxyphenyl)ethynyl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(4R,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(2-methylphenyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(4R,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(3-methylbut-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                                                  N-[[(4R,5S)-2-[(2S)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(4R,5S)-2-[(2S)-1-hydroxypropan-2-yl]-8-[2-(4-methoxyphenyl)ethynyl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(4R,5S)-8-(3-cyanophenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                                                  N-[[(4R,5S)-8-(3-cyanophenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                                                  N-[[(4R,5S)-8-[2-(1-hydroxycyclopentyl)ethynyl]-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(4R,5S)-8-[2-(1-hydroxycyclopentyl)ethynyl]-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(4S,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(2-methylphenyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(4S,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(3-methylbut-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                                                  N-[[(4S,5R)-2-[(2R)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(4S,5R)-2-[(2R)-1-hydroxypropan-2-yl]-8-[2-(4-methoxyphenyl)ethynyl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(4S,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(2-methylphenyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(4S,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(3-methylbut-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                                                  N-[[(4S,5R)-2-[(2S)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(4S,5R)-2-[(2S)-1-hydroxypropan-2-yl]-8-[2-(4-methoxyphenyl)ethynyl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(4S,5R)-8-(1-cyclopentenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                                                  N-[[(4S,5R)-8-(3-cyanophenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                                                  N-[[(4S,5R)-8-(3-cyanophenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                                                  N-[[(4S,5R)-8-[2-(1-hydroxycyclopentyl)ethynyl]-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(4S,5R)-8-[2-(1-hydroxycyclopentyl)ethynyl]-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(4S,5R)-8-bromo-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(4S,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(2-methylphenyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(4S,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(3-methylbut-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                                                  N-[[(4S,5S)-2-[(2R)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(4S,5S)-2-[(2R)-1-hydroxypropan-2-yl]-8-[2-(4-methoxyphenyl)ethynyl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(4S,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(2-methylphenyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(4S,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(3-methylbut-1-ynyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                                                  N-[[(4S,5S)-2-[(2S)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(4S,5S)-2-[(2S)-1-hydroxypropan-2-yl]-8-[2-(4-methoxyphenyl)ethynyl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-2-pyridinecarboxamide 0
                                                  N-[[(4S,5S)-8-(3-cyanophenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                                                  N-[[(4S,5S)-8-(3-cyanophenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-4-pyridinecarboxamide 0
                                                  N-[[(4S,5S)-8-[2-(1-hydroxycyclopentyl)ethynyl]-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[(4S,5S)-8-[2-(1-hydroxycyclopentyl)ethynyl]-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-pyridinecarboxamide 0
                                                  N-[[3-methoxy-4-[2-(4-methylanilino)-2-oxoethoxy]phenyl]methylideneamino]-3-pyridinecarboxamide 0
                                                  N-[[5-(4-nitrophenyl)-2-furanyl]methylideneamino]-3-pyridinecarboxamide 0
                                                  N-\{4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl\}pyridine-3-carboxamide 0
                                                  N-hydroxy-4-pyridinecarboxamide 0
                                                  N-methyl-4-pyridone-3-carboxamide + 0
                                                  N-methyl-6-pyridone-3-carboxamide + 1
                                                  N-methyl-N-[5-(3-pyridinyl)-1,3,4-thiadiazol-2-yl]-3-pyridinecarboxamide 0
                                                  N-methylnicotinamide 2
                                                  N-ribosyl-4-pyridone-3-carboxamide 0
                                                  acetic acid 2-[[oxo(3-pyridinyl)methyl]amino]ethyl ester 0
                                                  boscalid + 0
                                                  caerulomycin I 0
                                                  caerulomycinamide 0
                                                  cyclobutrifluram 0
                                                  diflufenican 0
                                                  flonicamid 0
                                                  florylpicoxamid 0
                                                  hydroxymethylnicotinamide 0
                                                  isonicotinamide + 8
                                                  motesanib 0
                                                  nicorandil 18
                                                  nicotinamide + 135
                                                  nikethamide 0
                                                  picolinafen 0
                                                  picolinamide 0
                                                  regorafenib + 13
                                                  sorafenib + 156
                                                  tert-butyl [2-(1,3-thiazol-2-ylcarbamoyl)pyridin-3-yl]carbamate 0
paths to the root

NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.